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Precision in redox signaling is attained through posttranslational protein modifications such as 
oxidation of protein thiols. The peroxidase peroxiredoxin 1 (PRDX1) regulates signal 
transduction through changes in thiol oxidation of its cysteines. We demonstrate here that 
PRDX1 is a binding partner for the tumor suppressive transcription factor FOXO3 that directly 
regulates the FOXO3 stress response. Heightened oxidative stress evokes formation of disulfide-
bound heterotrimers linking dimeric PRDX1 to monomeric FOXO3. Absence of PRDX1 
enhances FOXO3 nuclear localization and transcription that are dependent on the presence of 
Cys31 or Cys150 within FOXO3. Notably, FOXO3-T32 phosphorylation is constitutively 
enhanced in these mutants, but nuclear translocation of mutant FOXO3 is restored with PI3K 
inhibition. Here we show that on H2O2 exposure, transcription of tumor suppressive miRNAs let-
7b and let-7c is regulated by FOXO3 or PRDX1 expression levels and that let-7c is a novel 
target for FOXO3. Conjointly, inhibition of let-7 microRNAs increases let-7-phenotypes in 
PRDX1-deficient breast cancer cells. Altogether, these data ascertain the existence of an H2O2-
sensitive PRDX1-FOXO3 signaling axis that fine tunes FOXO3 activity toward the transcription 
of gene targets in response to oxidative stress. 
The public health significance of this research lies in the fact that elevated levels of 
oxidative stress in a major cancer risk factor. In breast cancer it has been found that post-
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 v 
menopausal women, who are generally at increased risk for breast cancer development, show an 
even higher level of oxidative stress markers. Unfortunately, antioxidant therapies have proven 
ineffectual. If we can gain a deeper understand of how these oxidative stress induced redox-
signaling pathways work, it is possible to develop more effective therapies for those at-risk 
patients for whom therapies fail. 
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1.0  INTRODUCTION 
1.1 BREAST CANCER 
Breast cancer is the most common new cancer diagnosis, and the second leading cause of cancer 
related death in American women after lung cancer. In 2017, it is estimated that in the United 
Sates, 252,710 women will be diagnosed with breast cancer, accounting for roughly 30% of all 
cancer diagnoses, and 40,610 women will die as a result of the disease, accounting for roughly 
14% of all cancer related deaths in women (1). Overall, an estimated one in every eight 
American women will develop an invasive breast cancer over the course of her lifetime (2). 
While being 100 times less prevalent in men than in women, men are still susceptible to breast 
cancer, with the lifetime risk of developing the disease at around one in one thousand. In 
addition, though it is rarer, breast cancer in men is usually considered more aggressive than 
breast cancer in women, as many men are not aware of their risk, and do not typically undergo 
screening. The American Cancer Society estimates that in 2017 there will be around 2,470 new 
invasive breast cancer diagnoses, and around 460 men dying from the disease (3). 
Given all of these statistics, it is clear that breast cancer is a serious public health concern, 
and therefore it is important to understand the underlying mechanisms which lead to breast 
cancer development and progression. With a greater understanding of what processes drive and 
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promote breast cancer, possible treatments can be devised so that diagnosis and mortality rates 
can decrease.  
1.1.1 Classification and stages 
Commonly, breast cancer is classified based on its cell of origin. Ductal carcinoma in situ 
(DCIS) and invasive ductal carcinoma (IDC) both originate in the inner tissue lining the milk 
ducts. Lobular carcinoma in situ (LCIS) and invasive lobular carcinoma (ILC) both originate 
from the milk-producing glands, or lobules (4). As the names suggest, both IDC and ILC have 
spread from their points of origin and invaded into the surrounding breast tissue. DCIS and LCIS 
are still confined to points of origin had have the ability to transition into invasive forms. IDC 
accounts for roughly 80% of all invasive breast cancers, while ILC accounts for about 10%. IDC 
can be broken down into further subtypes, medullary, mucinous, papillary, or cribriform 
carcinomas, each with unique cell morphologies, growth patterns, prognoses, and differences in 
effected populations (5).   
Breast cancer is categorized into stages 1-4, based on certain phenotypic criteria such as 
invasiveness, size, lymph nodes status, and metastases (6). DCIS is often termed stage “zero” as 
it is considered non-invasive, remaining limited to the duct and does not invade through the basal 
membrane. Once a tumor begins to increase in size and spread to the surrounding breast tissue 
and proximal lymph nodes, the cancer stage is upgraded. The extent of tumor size and 
invasiveness determines its categorization as stage 1, 2, or 3. A breast cancer is considered stage 
4 once the primary tumor has metastasized to other organs including distant lymph nodes, the 
lungs, liver, bone, and brain (7).  
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A stage four metastatic breast cancer diagnosis most often accompanies a poor prognosis, 
with a mortality rate of about 90% following diagnosis (8). A cancer becomes metastatic when 
primary tumor cells acquire properties through genomic events that allow them not only to break 
away from the tissue barrier of primary breast tumor and invade into blood and lymph vessels 
and travel to distant sites (9), but also to survive assaults from the immune system and drug 
interventions as they travel to the secondary sites. The changes often result in drug insensitivity, 
meaning that therapies that may have worked on the primary tumor are ineffectual in the 
treatment of metastatic tumors (10). In general, changes between the primary and metastatic 
tumors have also been shown to lead to a resistance to treatments which makes metastatic breast 
cancer all the more difficult to treat (11). 
1.1.2 Receptors 
Breast cancer is also categorized by their receptor profile. The three significant receptors 
involved in breast cancer are the estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2 or ERRB2)) (12). ER and PR are hormone receptors 
and localized intracellularly; when their ligands bind (estrogen or progesterone), ER and PR 
translocate into the nucleus and bind to hormone-responsive element (HRE) sequences located in 
the promoters of target genes. When bound to the DNA, ER and PR then regulate the expression 
of transcription factors which in turn regulate the expression of numerous genes involved in 
processes such as cell cycle control, DNA replication and repair, and apoptosis. Dysfunctions in 
ER/PR activity can lead dysregulation of their gene targets, and result in tumorigenesis (13-15). 
HER2 is a tyrosine kinase receptor bound to the plasma membrane and functions by dimerizes 
with other members of the epidermal growth factor receptor (ErbB) family (EGFR, ErbB3, 
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ErbB4). The dimerization causes autophosphorylation of tyrosine residues on HER2, triggering 
conformational changes that lead to other proteins binding, and inducing downstream signaling 
cascades (16). Inhibition or degradation of these signaling cascades can promote cancer 
progression by increasing cell survival, proliferation, motility, invasion, and metastasis. 
Based on a recently developed gene signature comprising 50 genes (pam50), breast 
cancer can be clinically divided into 4 subtypes (17). Accordingly, Lumina A breast cancers are 
positive for all three receptors, while Luminal B cancers are usually only positive for ER and PR. 
Hence, both groups are susceptible to estrogen based treatments, such as tamoxifen an estrogen 
antagonist, or aromatase inhibitors such as anastrozole, exemestane, and letrozole (18). Breast 
cancers only positive for HER2 show an over-expression of the HER2 receptor on the cell 
surface, resulting in increased growth factor binding and enhanced cell growth and proliferation 
beyond its normal limits. Drugs like Herceptin attach to the HER2 receptors, blocking them from 
receiving the excess growth signals, triggering the cell to arrest during the G1 phase of the cell 
cycle, and downregulate AKT activity (19). Breast cancers that do not express any of the 
aforementioned receptors are called triple negative, and belong according to the pam50 
classification to the basal subtype.  As this subtype does not express any of the druggable 
receptors (ER, PR or HER2), making them insensitive to endocrine or HER2 receptor targeting 
therapies, and thus very aggressive and difficult to treat (20). 
Understanding the underlying pathways that drive breast cancer development and 
progression may aid in the discovery and development of more effective therapies for those 
patients for whom current therapies fail. Oxidative stress and redox signaling is considered one 
such driver. 
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1.2 REACTIVE OXYGEN SPECIES AND OXIDATIVE STRESS 
Reactive oxygen species (ROS) are chemically reactive species containing oxygen and include 
superoxide anions (O2-), hydrogen peroxide (H2O2), and hydroxyl radicals (∙OH). Some ROS are 
also called free radicals and are characterized by unpaired valence electrons such as the hydroxyl 
radicals (∙OH) (Figure 1.1) (21). O2- is a product of the naturally occurring one-electron reduction  
 
 
Figure 1.1: Reduction of molecular oxygen. 
Molecular oxygen (O2) requires the addition of four electrons (e-) to be fully reduced to water (H2O) [Not 
shown as a balance equation] 
 
 
of molecular oxygen (dioxygen, O2). While single oxygen has two unpaired electrons that are 
shared in dioxygen and is relatively stable, O2- contains an additional electron, making it very 
reactive.  O2-  is a product of the naturally occurring one-electron reduction of molecular oxygen 
and for example a byproduct of mitochondrial respiration and produced at complex I and 
complex III of the electron transport chain (22). As with O2-, H2O2 is very short lived and a 
byproduct of biochemical reactions in the cell. For example, the O2- scavenging dismutase 
produces H2O2 in the process of eliminating O2-. Also, during catabolism of very long chain fatty 
acids in the peroxisomes, H2O2 is made. H2O2 is under acidic conditions one of the most 
powerful oxidizers known and can through catalysis be converted into (∙OH). For example, 
6  
during the Fenton reaction, ferrous (+2) iron is oxidized by H2O2 resulting in ferric (+3 ion), 
hydroxyl ion (OH-) and reactive ∙OH (22). 
ROS can be produced both endogenously and exogenously. Endogenously, ROS are 
produced in cellular compartments in which oxygen consumption is high, such as the 
mitochondria, peroxisomes, and the endoplasmic reticulum and enzymatically through NADPH 
oxidases. ROS can also be produced by various exogenous sources that include ionizing 
radiation, pollutants, tobacco and xenobiotics (Table 1.1) (22). ROS are capable of inducing 
oxidative modifications on various cellular components, such as DNA, proteins, and lipids. 
These modifications can play an essential role in protein functioning, and when at 
physiologically relevant levels, the ROS included changes are reversible. The reversibility of 
these changes allows for signals to be transduced to various downstream targets, this 
phenomenon is known as reduction and oxidation (redox) signaling (23). As opposed to other 
signaling mechanisms which may require a series of different enzymatic reactions in order to 
occur, oxidation requires none of that. ROS need only to be present in an environment, and 
oxidation susceptible targets accessible, for 
 
Table 1.1: Exogenous sources of ROS. 
Water & Air Pollution Heavy Metals (Fe, Cu, Co, Cr) 
Alcohol Transition Metals (Cd, Hg, Pb, As) 
Tobacco Smoke Drugs (Halothane, Doxorubicin, etc.) 
Pesticides Refrigerants 
Ultraviolet Light Industrial Cleaning Supplies 
(Adapted from Phaniendra et. al., 2015) (22) 
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oxidation to occur. As a result of the relatively few requirements for ROS induced oxidation, 
oxidation occurs fairly non-discriminately. While certain levels of ROS are beneficial to the cell, 
if ROS continue to accumulate and reach elevated levels, the changes will continue to occur, and 
the modifications will become irreversible, ultimately leading to permanent damage. This 
damage is referred to as oxidative stress (24). A redox homeostasis must be established within 
cells in order to carefully maintain a balance between the two different sides of ROS, oxidative 
stress and their role as signaling molecules. 
1.2.1 Oxidative stress induced damage 
Oxidative stress is the result of sustained accumulation of ROS, which regardless of origin, leads 
to non-specific oxidation. Uncontrolled and unchecked ROS accumulation and oxidative stress 
can result in lipid peroxidation, DNA mutagenesis, and protein dysfunction and damage. (21,25).  
In lipids, peroxidation by ROS can result in irreversible alterations to the lipid membrane, 
including loss of membrane function, changes in fluidity, and dysfunction in the transmembrane 
proteins (26,27). In DNA, high levels of ROS induce damage such as single and double stranded 
breaks, a-basic site formation, irregular DNA-protein crosslinking, and incorrect base pairing. 
Any one of these changes can result in incorrect or failed transcription; any resulting protein may 
contain altered amino acid sequence, and alterations can lead to either gain of function or loss of 
function of the protein (28,29). RNA is even more susceptible to the damaging effects of ROS 
since it is single-stranded, and therefore lacks a template and the common repair pathways in 
DNA (30). Finally, the most common cellular targets of oxidative stress are proteins, accounting 
for an estimated 70% of all ROS induced modifications in the cell (31). When amino acid 
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residues are indiscriminately oxidized by ROS, this leads to a multitude of altered residues 
(Table 1.2) (32) which may in turn negatively alter protein function (33).  
 
Table 1.2: ROS mediated oxidation of protein amino acid residue side chains. 
Amino Acid Product 
Arginine Glutamic-semialdehyde 
Cysteine Cysteine disulfides; Sulfenic acid 
Histidine  2-oxo-histodine 
Leucine 3-,4-,5-hydroxyleusine 
Lysine 2-Amino-adipic-semialdyhyde 
Proline Glutamic-semialdehyde; 2-pyrrolidone; 4-,5-
hydroxyproline 
 
Threonine 1-amino-3-keto butyric acid 
(Adapted from Stedtman et. al., 2003) (32). 
 
Altogether, the oxidative stress induced damage to lipids, DNA/RNA, and proteins due to 
elevated ROS levels results in considerable alterations to protein function and inevitably lead to 
numerous severe physiological conditions due to disruptions to various pathways and processes 
involved in such conditions. Left uncontrolled, ROS accumulation and oxidative stress have been 
shown to contribute to and promote a wide array of human diseases, including aging, obesity, 
cardiovascular diseases, neurodegenerative diseases, and many forms of cancer (34-38). It is not 
an understatement to say that the negative effects of ROS are far reaching and impact every 
living creature. 
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1.2.2 Redox signaling 
While the damaging effects of ROS accumulation are well documented and severe, organisms 
actually require ROS to survive, and H2O2 is considered a second messenger (39). Thus, the 
biological role ROS play in redox signaling has seen a significant growth in attention and 
importance in the past couple of decades (40,41). 
For example, one well understood benefit of ROS is demonstrated in immune defense 
(42). NOX2, an NADPH oxidase comprised of six subunits, gp91phox and p22phox are membrane-
bound components, whereas p47phox, p67phox, and p40phox are all cytosolic components that 
assemble with the membrane-bound portion upon activation of either Rac1 or Rac2 GTPases. 
NOX2 converts molecular oxygen to superoxide anions as a mechanism to eliminate bacteria 
(43,44). NOX2 activity is essential as patients who carry a mutation in the gp91 subunit develop 
an immunodeficiency called chronic granulomatous disease (CGD) which is characterized by 
frequent bacterial infections (45). 
Another example of redox signaling is the regulation of the phosphatase and tensin 
homolog (PTEN) that is a widely expressed tumor suppressive protein which functions as a lipid 
and tyrosine phosphatase and inhibitor of the PI3K/AKT cellular proliferation and longevity 
signaling pathway. PTEN belongs to the group of protein tyrosine phosphatases which use the 
nucleophilic cysteine thiolate in their active site to remove phosphate groups from tyrosine by 
building a cysteinyl-phosphate enzyme intermediate. In the absences of PTEN, PI3K converts 
phosphatidylinositol (4,5)-triphosphate (PIP2) to phosphatidylinositol (3,4,5)-triphosphate (PIP3), 
and phosphorylates AKT, causing AKT to activate and localize to the cell membrane where it 
can initiate a number of downstream effects, many of which when constitutively active, are 
involved in tumorigenesis. When active, PTEN functions to dephosphorylate PIP3 back to PIP2, 
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thereby limiting AKT membrane binding, and decreasing its activity (46). However, upon 
oxidation of the active site cysteine (Cys124) in PTEN by hydrogen peroxide an intra-disulfide 
bond forms between Cys124 and the N-terminal Cys71 that inhibits PTEN’s phosphatase 
activity, and allowing for the activation of AKT. Maintaining a careful balance between 
unoxidized and active PTEN and oxidized and inactive PTEN, is therefore important for proper 
PI3K/AKT signaling activity (47,48). 
Through the reversible oxidation of thiol-containing amino acid residues of target 
proteins, ROS are capable of regulating a diverse range of biological processes as a result of their 
ability to transduce a signal (49,50). Protein targets of redox signaling include transcription 
factors, receptors, enzymes, and proteases. Some of the cellular processes modified by redox 
signaling include aging, cell growth and proliferation, and apoptosis (51).  
1.2.3 Cysteine oxidation 
As previously mentioned, ROS oxidize thiol-containing amino acid residues in order to regulate 
target protein activity. Cysteine is the primary amino acid susceptible to oxidation within a 
protein, contributing most to the protein’s overall redox sensitivity (52). Briefly, in the presence 
of ROS such as H2O2, the thiol (-SH) gets oxidized to a thiolate (-S-), which upon further ROS 
stimulation, is oxidized further into sulfenic acid (-SOH), the precursor to disulfide bonds. The 
oxidation of thiol to thiolate to sulfenic acid is reversible, and the disulfide bonds formed can be 
reduced upon reaction with a reducing agent such as thioredoxin (TRX). Cysteine can be further 
oxidized from sulfenic acid into sulfinic acid (SO2H), and then from sulfinic acid into sulfonic 
acid (SO3H). These oxidations, however, are irreversible and result in permanent protein damage 
(Figure 1.2) (50).  
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Figure 1.2: Stepwise oxidation of cysteine residues. 
Oxidation of the sulfur atom within a cysteine residue can result in the stepwise formation of a reactive 
cysteine thiolate, sulfenic acid, sulfinic acid, and finally sulfonic acid. With the aid of a reducing agent, 
the oxidation to thiolate and sulfenic acid is reversible. Oxidation to sulfinic or sulfonic acid is 
irreversible. 
 
While cysteine is considered the most physiologically relevant amino acid reside due to 
its thiol group, its position within a folded protein, and the surrounding residues do play a part in 
cysteines reactivity. Cysteine has a high acidic dissociation constant (pKa) of approximately 8.2, 
so at physiological pH, it is more likely to be found in its protonated and therefore less reactive 
thiol state. However, if a cysteine is surrounded by positively charged amino acid residues, the 
pKa, can be lowered to such a level that the cysteine can exist as a deprotonated nucleophilic 
thiolate, greatly increased its and the protein’s redox sensitivity (31,50). 
Arguably, one of the most significant outcomes resulting from the oxidation of cysteine’s 
thiol in terms of redox signaling, is its ability to form reversible disulfide bonds with other thiol 
functional groups. In the presence of ROS, a thiolate group can be oxidized into a sulfenic acid 
intermediate, which then can react with another thiol (both intra- or inter-molecularly), creating a 
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reversible disulfide bond (53). Disulfide bond formation can have a great impact on protein 
structure, stability, and function. Often, a disulfide is required for proper protein folding, and the 
absence of the bond would result in a dysfunctional or inactive protein (54). Oxidation of a thiol 
and disulfide bonds have another important function in redox signaling, and that is acting to 
regulate the activity of other proteins. One of the better understood methods of protein regulation 
is through a mechanism known as the thiol-disulfide exchange, and is also thought to have a role 
in intra- and intermolecular redox homeostasis (55). In short, due to their negative charge, 
thiolate anions (S-) are highly reactive because of their availability of electrons, and therefore 
will readily react with other reactive species in order to become more stable and neutralize their 
negative charge. During the thiol-disulfide exchange, a reactive thiolate anion ‘attacks’ one of 
the sulfur atoms of a disulfide bond. The original disulfide bond then begins to break as a new 
one forms, creating a trisulfide-like transition state, a “tri-thiol” ion (56). Eventually the original 
disulfide is entirely broken, and a new disulfide bond containing the ‘attacking’ thiolate is 
formed, along with the release of a new thiolate anion (Figure 1.3) (57). This reaction is highly 
transient, with the newly formed thiolate free to go on and react, possibly forming or reforming 
other bonds and triggering further downstream reactions. In summary, disulfide bond 
formation’s role in protein folding, stabilization, activation, and regulation, and the transient 







Figure 1.3: Thiol-disulfide exchange. 
The thiolate group on protein X1 attacks a sulfur atom of protein X2 of the disulfide bond, creating a 
temporary “tri-thiol” ion, and ultimately displacing the other sulfur atom in the disulfide (protein X3) and 
forming a new disulfide bond between proteins X1 and X2, and a new thiolate ion on protein X3. 
1.2.4 Antioxidants  
As discussed above, accumulation of ROS can cause permanent damage and dysfunction on both 
the cellular and organismal levels. Fortunately, cells have a way to combat detrimental effects in 
the form of antioxidants that inhibit the oxidation of other molecules. Antioxidants include 
vitamins, minerals, flavonoids and antioxidant enzymes. When there is a buildup of ROS in a 
cell or in the cellular environment, antioxidants restore redox homeostasis by neutralizing the 
ROS into non-reactive products and repairing any erroneously oxidized molecules before 
permanent damage can occur. The importance of antioxidants is highlighted by the fact that loss 
of antioxidant activity has been shown to be a contributing factor in numerous diseases (58,59).  
Enzymatic antioxidants such as superoxide dismutase (SOD), catalase, thioredoxins, 
glutathione peroxidase, and peroxiredoxins, all function to detoxify any excess ROS, often 
working in combination and in a stepwise fashion (Figure 1.4) (60). As an example, SOD can 
convert two superoxide anions into hydrogen peroxide and molecular oxygen (60). The hydrogen 
peroxide can then immediately be converted by catalase into water and another molecular 
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oxygen. Glutathione peroxidase, with glutathione as a co-factor, and peroxiredoxin, using 
thioredoxin as an electron donor, can also reduce hydrogen peroxide to water and molecular 
oxygen (61,62). This redundancy in antioxidant activity, with multiple different antioxidants able 
to reduce the same ROS, highlights their importance in the cell, and the importance of 
neutralizing any ROS accumulation. 
 
Figure 1.4: Neutralization of ROS by antioxidants. 
SOD: Superoxide dismutase; TRX: Thioredoxin; GPX: Glutathione peroxidase; PRDX: Peroxiredoxin. 
[Not shown as a balance equation] 
 
Besides their function as ROS detoxifying agents, antioxidants also play a role in redox 




Peroxiredoxins (PRDXs) are a family of six ubiquitous hydrogen peroxide scavengers (PRDX1-
6), antioxidant enzymes that reduce hydrogen peroxide (H2O2) via the oxidation of a peroxidatic 
(or catalytic) cysteine to sulfenic acid (63). The peroxiredoxins can be subdivided into three 
main subclasses based on their cysteine complement: typical 2-Cys PRDXs (PRDX1-4), atypical 
2-Cys PRDX (PRDX5), and 1-Cys PRDX (PRDX6) (64,65). The names 1-Cys and 2-Cys do not 
refer to the numbers of cysteines actually present in the protein, but rather the number of 
cysteines active in the catalysis of hydrogen peroxide. 1-Cys PRDX has only one cysteine 
involved, while 2-Cys PRDXs have two. The difference between typical and atypical 2-Cys 
PRDXs is that the typical 2-Cys PRDXs form a disulfide bond between two different PRDX 
proteins, forming a homodimer, while the atypical 2-Cys PRDX forms the disulfide between two 
cysteines within the same protein (66). In contrast to the 2-Cys PRDXs, in the catalytic cycle of 
PRDX6, the only 1-Cys PRDX, the single C-SOH does not form a disulfide bond, as another C-
SH is unavailable. PRDX6 oxidized at the peroxidatic cysteine is reduced by glutathione (67).  2-
Cys PRDXs contain a thioredoxin binding domain, which is necessary to disulfide bond 




Figure 1.5: PRDX1 as example of typical 2-Cys PRDX domain structure. 
Peroxidatic cysteine (C52) and resolving cysteine (C173) are shown in red, along with other cysteines 
present in the protein. 
 
1.3.1 PRDX1 oxidation  
As mentioned above, all PRDX proteins contain a cysteine known as the peroxidatic cysteine 
(CP) which can be found in the N-terminal domain. It is this cysteine that reacts with hydrogen 
peroxide during catalysis. In PRDX1, this is C52. In the majority of PRDXs, there is a second 
evolutionarily conserved resolving cysteine (CR) found in the C-terminal domain, that allows for 
an intermolecular disulfide bond to form between two PRDX molecules. In PRDX1, this is C173 
(68). 
In the presence of hydrogen peroxide, PRDX1 C52 is oxidized to a sulfenic acid (C52-
SOH). The sulfenic acid can then react with the thiol of C173 (C173-SH) in a second PRDX1 
molecule, forming an intermolecular disulfide bond and a head to tail PRDX1 dimer (66). Unlike 
some other antioxidant enzymes that can be reduced by various other reducing agents, PRDX1, 
like other 2-Cys PRDXs, can only be reduced via a thiol-disulfide exchange by TRX, which was 
mentioned before as another antioxidant involved in redox control. Thus, the reducing 
equivalents responsible for restoring PRDX1’s catalytic activity come from NADPH via 
thioredoxin reductase (TRXR) and TRX (Figure 1.6) (69). 
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Compared to other antioxidants like catalase, PRDXs are very sensitive to ROS, and have 
a high affinity for H2O2, functioning at relatively low to moderate concentrations. Catalase, 
which reduces H2O2 following an exponential decay, the reduction rate depends linearly on 
hydrogen peroxide concentration (70), functions fast and efficiently when H2O2 concentrations 
are high. However, once concentrations drop to a certain level, PRDXs can scavenge more 
efficiently due to their higher affinity. Because of the high affinity to H2O2, PRDX1 can be very 
easily over-oxidized from sulfenic acid to sulfinic or sulfonic acid at its peroxidatic cysteine,  
 
Figure 1.6: The PRDX1 oxidation cycle. 
In the presence of H2O2, the peroxidatic cysteine of PRDX1 (C53), is first deprotonated to a thiolate anion 
and then further oxidized to sulfenic acid. In the sulfenic acid, C52 can form a disulfide bond with the 
resolving cysteine (C173) of a second PRDX1 molecule, creating a PRDX1 homodimer and releasing a 
water molecule. The dimer can be reduced by thioredoxin (TRX) to restore PRDX1’s peroxidase activity 
[cycle shown in box]. Further oxidation by H2O2 leads to the formation of sulfinic acid and sulfonic acid, 
both reactions are irreversible.
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blocking its antioxidant activity (71). One possible explanation that has been suggested for the 
easy over-oxidation of C52, is that during catalysis C52 exists as a thiolate (C52-S-) whilst the 
three other cysteines (C71, C83, and C173) all remain protonated as thiols. As discussed above, 
thiolates are nucleophilic and highly unstable, and will react with any available thiol to form 
either a disulfide bond, or to irreversibly oxidize further into sulfinic or sulfonic acid (72).  
Interestingly, examinations of the crystal structures of both PRDX1 and PRDX2 showed 
that their peroxidatic cysteines can be stabilized and protected in its thiolate state within a folded 
N-terminal active site pocket, by forming salt bridges with other amino acid residues nearby due 
to protein folding (notably arginine and threonine) (73,74). This, of course, begs the question, if 
a thiolate can be stabilized and protected, what exactly causes the over-oxidation observed 
during catalysis? It was found that over-oxidation is correlated with an increased presence of 
TRX (75). Investigators speculate that when TRX binds to PRDX1 to reduce the disulfide, the 
reduced C52-SH becomes susceptible to over-oxidation due to TRX blocking the sequestration 
of the reduced C52 into the active-site, thus exposing it to hydrogen peroxide present (68).  
While over-oxidation of PRDX1 does trigger a loss of antioxidant activity, it does not 
render PRDX1 useless or non-functional. Rather, over-oxidation of PRDX1 functions as an 
effective switch over to molecular chaperone function in the form of a decamer composed of five 
homodimers (76,77). 
1.3.2 Cell signaling through PRDX1 
PRDX1 plays an active role in redox signaling, regulating the activity protein binding partners 
involved in a number of cellular processes and biological pathways. Under increased H2O2 
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stress, PRDX1 shows a decreased affinity for certain signaling molecules, and can increase the 
dissociation of PRDX1 from said molecules. The loss of complex formation can then lead to the 
activation (e.g. c-Abl) or inactivation of PRDX1’s binding partners (e.g. PTEN, MKP-1). Other 
binding partners have been described to enhance activity once bound to PRDX1 (e.g. MKP-5 and 
MST1) or inactivity (e.g. JNK) (78-80).  
As discussed previously, the nucleophilic cysteine in the active site of the PTP-PTEN is 
required for dephosphorylation of it substrate, but because of this it is very sensitive to oxidation. 
Interestingly, it’s been shown that PRDX1 binds to PTEN under mild H2O2 stress, promoting 
PTEN membrane binding, and fully protecting PTEN lipid phosphatase activity from any 
oxidation induced inhibition (78). However, as H2O2 concentrations increase and PRDX1 C52 
becomes over-oxidized and the PRDX1-PTEN interactions breaks, leaving PTEN susceptible to 
inactivating oxidation, inhibition of its phosphatase activity, and subsequent tumorigenesis by 
way of overexpressed PI3K/AKT downstream targets. 
Mammalian Ste20-like kinase-1 (MST1), like PTEN, is another binding partner activated 
through an interaction with PRDX1. MST1 is a Ser/Thr protein kinase. In response to apoptosis 
inducing stimuli such as H2O2 accumulation, MST1 autophosphorylates, which allows it to 
phosphorylate target proteins, and ultimately trigger cell death mechanisms (81). The 
phosphorylation of transcription factors like FOXO family members in mammalian cells, and 
histone subunits in yeast, are just some examples of the cell death pathways activated by MST1 
and its homologs (82,83). It is an association with PRDX1 by which MST1 mediates these 
apoptotic pathways. It is assumed that in response to H2O2, PRDX1 decamers form an 
oligomeric complex with MST1, thus interfering with the MST1 inhibitory domain and 
protecting the autophosphorylation domain, thereby enhancing MST1 activation. As expected, in 
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the absence of PRDX1 or decreased oligomerization, MST1 shows decreased 
autophosphorylation levels and decreased activity (79). 
PRDX1 binding does not just activate its partners, but can also lead to their inactivation 
or inhibition. JNK, or c-Jun N-terminal kinases, are a group of kinases originally identified as 
phosphorylating the c-Jun subunit of the transcription factor AP-1 but have been shown to 
phosphorylate a number of nuclear substrates, mostly transcription factors. Interestingly, in a 
study examining PI3K-driven tumorigenesis in PTEN loss of function mutants, it was found that 
the JNK signaling pathway was enriched as a downstream target of PI3K activity. However, 
while it had been previously established that constitutively active PI3K was sufficient to trigger 
JNK activation (84), upregulation of JNK activity was found to be independent of AKT 
activation, suggesting that the JNK and AKT pathways, while both regulated PI3K and PTEN, 
work in parallel to one another instead of linearly to promote tumorigenesis (85). One common 
inhibitory mechanism of JNK is the formation of a complex between the C-terminal domains of 
phosphorylated glutathione S-transferase P1 (GSP1) and JNK, preventing JNK from 
phosphorylating its downstream targets. The dissociation of this GSTP1-JNK complex via stress 
stimuli (gamma irradiation, heat shock, oxidative stress, etc.) restores JNK activity (86). It’s been 
shown, however, that PRDX1 is able to bind to the GSTP1-JNK complex, preventing the release 
of JNK, insuring JNKs further inhibition, and suppressing JNKs activity, even following a stress 
stimulus like irradiation. Interestingly, when the peroxidatic cysteine was overoxidized or 
mutated into a serine, and therefore catalytically inactive, PRDX1 was still able to bind to the 
GSTP1-JNK complex. This finding suggests that PRDX1’s JNK inhibitory function is 
independent of its antioxidant activity (80). 
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As mentioned above, PRDX1 displays two functions, one as an antioxidant, neutralizing 
hydrogen peroxide to prevent the damaging effects of ROS build-up and the other one as a key 
signaling molecule that is capable of using its oxidation by hydrogen peroxide as a secondary 
messenger. With both functions, PRDX1 regulates the activity of many cellular processes, 
activating and inhibiting numerous biological pathways, and even playing a role in several 
diseases and dysfunctions. 
1.3.3 PRDX1 and cancer  
As discussed in the previous section, PRDX1 is involved in the regulation of many cell signaling 
pathways and biological processes, and as a result of this involvement, plays a role in the 
development and progression of many diseases, the most paramount of which is cancer. In a 
study in which PRDX1 was knocked out in mice, it was found that the mice lacking PRDX1 
(Prdx1-/-) had significantly decreased lifespans as compared to mice containing one or both 
copies of PRDX1 (WT and Prdx1+/-). In addition, the mice lacking at least one copy of PRDX1 
developed, and eventually succumbed to severe hemolytic anemia and several types of 
malignancies, including pancreatic cancer, lung cancer, and breast cancer (87). Similar findings 
were found in a Caenorhabditis elegans model, in which C. elegans lacking cytosolic 2-Cys 
PRDXs were short-lived and showed signs of accelerated aging (88). Taken together, these 
findings suggest that PRDX1 possesses some tumor preventive functions.  
Many have investigated PRDX1’s tumor preventative function, and found that it is 
conferred through the regulation of signaling molecules involved in pathways responsible for cell 
death and apoptosis, cell cycle arrest, and cell growth and cell proliferation. PRDX1 protects the 
tumor suppressor PTEN from oxidative stress induced degradation. As mentioned before, by 
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binding to and protecting PTEN, PRDX1 thereby enables PTEN to regulate AKT levels, and 
maintain a proper balance of cell death and proliferation, and inhibiting tumorigenesis (78). 
Acting as an intermediary for the critical tumor suppressor p53, PRDX1 oligomers bind to 
MST1, activating the kinase which then goes on to regulate apoptotic pathways (79). Shown in 
lung cancer, PRDX1’s binding to the GSTP1-JNK complex, preventing the release of the kinase 
JNK, inhibits JNK activity (80). 
While for the most part PRDX1 is considered to be a tumor preventer, aiding in the 
regulation of many tumorigenesis inhibitory pathways, the antioxidant has been shown to play a 
tumor supportive role as well. When looking at its relationship with the mitogen-activated 
protein kinase (MAPK) p38α, PRDX1 acts as a redox specific sensor in cellular senescence. As 
demonstrated in breast cancer, PRDX1 differentially associates with and regulates the MAPK 
phosphatases MKP-1 and MKP-5, depending on its oxidation state. Both MKP-1 and MKP-5 
dephosphorylate and deactivate the senescence inducing p38α. These MKPs have a low pKa 
catalytic cysteine residue within a conserved active site, and as a result, at physiologically 
normal pH levels this cysteine is susceptible to oxidation. Oxidation at the catalytic cysteine 
leads to loss of the protein’s phosphatase activity, and the formation of a disulfide-based 
oligomeric structure  (89,90). However, PRDX1 binding does depend on concentration of H2O2, 
and oxidation state of PRDX1 C52. Under H2O2-indused stress, PRDX1 dissociates from MKP-
1, which then allows for the oligomerization of MKP-1, and the loss of its phosphatase activity 
towards p38α. In contrast to MKP-1, under high concentrations of H2O2, PRDX1 binding to 
MPK-5 was promoted, protecting MKP-5 from oxidation-induced inactivation, and actually 
promoting MKP-5’s phosphatase activity towards p38a. Over oxidation of PRDX1 C52 was also 
found to be enhanced in the PRDX1 – MKP-5 complex. Taken together, these findings suggest 
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that PRDX1 fine tunes MPK/p38a signaling in a dose-dependent manner by way of C52’s 
oxidation status (91).  Interestingly, in pancreatic cancer, PRDX1 was found to co-localize with 
phosphorylated (active) p38α, and form complexes at the leading edge of migrating pancreatic 
cancer cells, suggesting PRDX1 plays a role promoting tumor cell invasion though an interaction 
with p38α (92). 
PRDX1’s role in tumorigenesis, both inhibitory and protective, is complex. It is only by 
investigating its functions beyond that of simply mitigating ROS induced stress, by studying the 
different processes in which PRDX1 is involved, identifying its binding partners, and 
determining the various mechanism by which it acts, that we may gain a deeper understanding of 
full extent of PRDX1’s biological role. Recently, the transcription factor known to have a role in 
cancer, FOXO3 was identify through mass spectroscopy as a possible PRDX1 binding partner 
(93). 
1.4 FOXO3: AN ESSENTIAL TUMOR SUPPRESSOR 
First identified in C. elegans, the Forkhead box (FOX) transcription factors are superfamily of 
transcription factors which contain an evolutionarily conserved DNA binding domain (DBD) 
known as the forkhead box or winged helix domain (WHD). Variations in sequence outside of 
the DNA-binding domain between the smaller FOX subfamilies (FOXA-R), lead to significant 
differences in regulation, protein function, and distribution within a body (94).  
The Forkhead Box, Class O (FOXO) subfamily consists of four proteins, FOXO1, 
FOXO3, FOXO4, and FOXO6, and contains a conserved GDSNS amino acid sequence inserted 
within the DNA-binding domain, which is missing in the other FOX proteins (95). In addition to 
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the unique DNA-binding domain, FOXO proteins also contain three other conserved domains; a 
nuclear localization signal (NLS), a nuclear export sequence (NES), and the transactivation 
domain (TA) (Figure 1.7) (96). While all FOXOs are expressed at basal levels in most tissues, 
the different isoforms can be tissue specific. FOXO1 is more highly expressed in the ovaries and 
fat tissue, FOXO3 is found at high levels in skeletal muscle, and FOXO6 can be found in the 
hippocampus and amygdala, suggesting it may play an important role in cognitive function 
(97,98). 
1.4.1 DNA-binding domain structure 
The evolutionarily conserved DNA-binding domain contains three α−helices (H1-3), three β-
sheets (S1-3), and two loops known as ‘wings’ (W1-2) which protrude from and connect β-
sheets. The N-terminal domain is formed by H1-S1-H2-H3, while the C-terminal domain is 
formed by S2-W1-S3-W2 (99). Conserved amino acid residues (N208, R221, H212, and S215) 
within H3 of the N-terminal domain, recognize the FOXO consensus binding domain 
(GTAAA(C/T)A) in target genes, and interact with the major groove of the DNA through 
hydrogen bonds and van der Waals forces (100). The two β-sheets (S2 and S3) of the C-terminal 
domain interact with the minor groove, while the two wings interact with the phosphate 




Figure 1.7: FOXO3 as example of FOXO domain structure. 
DBD: DNA binding domain; TA: Transactivation Domain; NLS: Nuclear Localization Signal; NES: 
Nuclear Export Signal. AKT phosphorylation sites (T32, S253, and S318) shown in red. 
 
1.4.2 Post-translational modification 
FOXO activity is highly regulated through post-translational modifications (PTM) such as 
phosphorylation, acetylation, and ubiquitination (102).  
Phosphorylation by the kinase AKT is a key negative regulator of FOXOs. AKT 
phosphorylates FOXO at specific serine or threonine residues (T32, S253, and S315 on FOXO3), 
which generates a binding site for the chaperone protein 14-3-3 (103). 14-3-3 binding to a FOXO 
protein phosphorylated at any one of the three AKT sites obscures the nuclear localization signal, 
thereby preventing nuclear entry or re-entry. 14-3-3 binding also results in a conformational 
change that exposes the nuclear export sequence, so that any FOXO present in the nucleus is 
subsequently expelled (Figure 1.8). As an end result, AKT phosphorylation of FOXO proteins, 
and the subsequent binding of 14-3-3, sequesters the transcription factor in the cytoplasm, 
inhibiting transcriptional activity (104). Phosphorylation by AKT can also trigger other 
subsequent PTMs discussed later. 
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 Phosphorylation can also lead to nuclear import and accumulation of FOXO proteins, 
some examples of which are by the kinases MST1, JNK, and p38α in FOXO3 (82,105,106). 
Phosphorylation by these kinases results in a disruption of 14-3-3 binding to FOXO3 in the 
cytoplasm, allowing it to accumulate in the nucleus and bind to its protein targets (99).  MST1 
phosphorylates at S209, JNK at S574, and p38α at S7. Interestingly, as was discussed 
previously, PRDX1 has been shown to regulate the activities of all three of these kinases, 





Figure 1.8: 14-3-3 binding regulates FOXO3 localization. 
AKT phosphorylates FOXO3 on three sites, including one proximal to the nuclear localization sequence 
(NLS). 14-3-3 can bind to phosphorylated FOXO3, covering the NLS, thus preventing nuclear 
translocation. 14-3-3 binding triggers a conformational change, exposing the nuclear export signal (NES) 
so that if FOXO3 is phosphorylated within the nucleus, binding triggers nuclear expulsion. Binding of 14-




Other PTMs exist which also influence FOXO activity. One example of a modification is 
the susceptibility of lysine residues in FOXO proteins (K242 and K245 in FOXO3) to acetylation 
by cAMP-response element binding (CREB)-binding protein (CBP) (96). The acetylation of 
these residues decreases the affinity of FOXO for the consensus sequence found in target DNA, 
thereby, leading to the FOXO-DNA complex to become less stable. It has also been proposed 
that acetylation at these lysines leads to an increase in phosphorylation at the AKT 
phosphorylation site, S253, found nearby (101). Interestingly, it has been shown in FOXO4 that 
acetylation of the lysine residues by CBP is mediated through a redox sensitive disulfide bridge 
between cysteines on FOXO4 and CBP. Under H2O2 induced stress, the bridge between FOXO4 
and CBP forms, allowing CBP to acetylate FOXO4’s lysines. TRX can then come in, reduce the 
cystine disulfide through an intra-disulfide-thiol exchange, thereby releasing the acetylated 
FOXO4 molecule (107). This finding suggests redox and cysteine oxidation could play a role in 
other forms of FOXO regulation. 
Finally, FOXO proteins can be regulated by mono- and polyubiquitination, which can 
both increase and decrease transcriptional activity (96). In the case of FOXO4, 
monoubiquitination increases activity. Certain lysine residues found in the nuclear localization 
signal (K199 and K211) can be monoubiquitinated under oxidative stress conditions. This 
monoubiquitination interferes with and disrupts the acetylation of other nearby lysines, which 
would otherwise lead to a decrease in nuclear localization and decreased activity (108). In 
FOXO1 and FOXO3, polyubiquitination at key lysine residues such as K63, in conjunction with 
phosphorylation, can promote proteasomal degradation. Phosphorylation by AKT triggers the 
binding of the FOXO1 or FOXO3 to MDM2, an E3 ubiquitin ligase, which then promotes the 
polyubiquitination and eventual degradation of the FOXO protein (109). Independent of AKT, I 
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kappa B kinase b (IKKb) has been shown to phosphorylate FOXO3 at S644 which leads to the 
polyubiquitination of K63 by an E2-E3 ubiquitin ligase complex composed of Rad6 (E2) and 
Bre1 (E3) (110,111).  
1.4.3 FOXO3 function 
Like the other members of the FOXO family, FOXO3 acts as a tumor suppressor, regulating the 
transcription of gene targets which play integral roles in a number of cellular pathways such as 
apoptosis, cell cycle arrest, and resistance to oxidative stress (Table 1.3). (96). 
FOXO3 activates the expression of a number of pro-apoptotic proteins, such as FasL and 
BIM. FOXO3 binding to the FOXO consensus sequence in the Fas receptor ligand (FasL) 
promoter leads to the upregulation of FasL, a transmembrane protein which when bound to the 
Fas receptor, activates the Fas-dependent cell death pathway through the activation of caspase 8 
(112-114). FOXO3 has also been shown to upregulate the expression of Bcl-2-like protein 11 
(BIM), a member of the pro-apoptotic Bcl-2 family. Once transcribed, BIM forms either homo- 
or heterodimers with other Bcl-2 proteins. The dimer then releases cytochrome c into the 
cytoplasm, and apoptotic protease activating factor-1 (Apaf-1) is in turn activated, forming an 
oligomeric apoptosome, leading to apoptosis (112).  
FOXO3 is also known to regulate the cell cycle, specifically to induce the expression of 
cell cycle inhibitors, an example of which is the cyclin-dependent kinase (CDK) inhibitor, 
p27kip1 (p27) (115). p27 functions by binding to either the cyclinE-CDK2 or the cyclinD-CDK4 
complex, preventing the complex’s function and leading to its ultimate inactivation. When either 
complex is inactivated, cell cycle arrest is induced at the G0 to G1 phase (116). It’s also been  
 
30  
Table 1.3: FOXO3 target genes. 
Gene (Protein) Function Reference 
BCL2L11 (BIM) Apoptosis Gilley et al. 2003 (117) 
FASLG (FasL) Apoptosis Brunet et al. 1999 (118) 
TNFSF10 (TRAIL) Apoptosis Modur et al. 2002 (119) 
BBC3 (PUMA) Apoptosis Ekoff et al. 2007 (120) 
PMAIP1 (NOXA) Apoptosis Obexer et al. 2007 (121) 
BCL6 (BCL6) Apoptosis Fernández de Mattos et al. 2004 (122) 
NOLC1 (P130) Cell Cycle Control Kops et al. 2002 (123) 
CDKN1A (p21) Cell Cycle Control Seoane et al. 2004 (124) 
CDKN1B (p27) Cell Cycle Control Medema et al. 2000 (125) 
CCND1 (Cyclin D1) Cell Cycle Control Ramaswamy et al. 2002 (126) 
CCND2 (Cyclin D2) Cell Cycle Control Ramaswamy et al. 2002 (126) 
CCNG2 (Cyclin G2) Cell Cycle Control Martínez-Gac et al. 2004 (127) 
GADD45 (GADD45) DNA Repair Furukawa-Hibi et al. 2002 (128)  
DDB1 (DDB1) DNA Repair Ramaswamy et al. 2002 (126) 
SOD2 (MnSOD) Oxidative Stress Kops et al. 2002 (129) 
CAT (Catalase) Oxidative Stress Nemoto and Finkel. 2002 (130) 
TXNIP (TXNIP) Oxidative Stress Papadia et al. 2008 (131) 
SESN3 (Sestrin 3) Oxidative Stress Nogueira et al. 2008 (132) 
IGFBP1 (IBP-1) Cell Growth Yang et al. 2016 (133) 
GOLPH3 (Golph3) Cytoskeletal Adhesion Eijkelenboom et al. 2013 (134) 
CIDEA (CIDEA) Milk Production Pelosi et al.  2013 (135) 
FOXC2 (FOXC2) Transcription Factor Pelosi et al.  2013 (135) 
GALT (GALT) Metabolism Halperin et al. 2007 (136) 
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found that when FOXO3 is sequestered in the cytoplasm, rendering it transcriptionally inactive, 
there is a corresponding decrease in the expression of cyclin D, which too leads to an arrest of 
cell cycle progression, adding another layer of regulation by FOXO3 (137). 
Lastly, FOXO3 has also been shown to upregulate targets associated with oxidative stress 
resistance, including manganese superoxide dismutase 2 (MnSOD2) and catalase (129,130). As a 
reminder, MnSOD2 like SOD, catalyzes the reaction that converts superoxide ions (O2-) into 
hydrogen peroxide (H2O2) and oxygen (O2). Catalase then catalyzes the further reaction of 
hydrogen peroxide into water and molecular oxygen. This upregulation of ROS detoxifying gene 
targets by FOXO3 serves to protect the cell from oxidative stress induced damage. 
1.4.4 FOXO3 and cancer 
As stated before, FOXO3 is considered to be a tumor suppressor with the ability to regulate a 
number of cellular functions involved in tumorigenesis, including cell cycle progression and 
apoptosis. When sequestered in the cytoplasm, FOXO3 is rendered inactive, inhibiting the 
transcription of FOXO3’s cell cycle inhibitor and pro-apoptotic gene targets. As a result of the 
inhibition of these targets, cells can turn malignant, giving rise to a number of different cancer 
types, including breast cancer (110). 
Numerous studies have been published showing the protective role FOXO3 plays in 
decreasing and inhibiting breast cancer tumorigenesis. FOXO3 is known to inhibit estrogen-
dependent cancer cell proliferation. Through interactions with ER-α and ER-β proteins, FOXO3 
inhibits 17β-estradiol(E2)-dependent and ER-regulated transcriptional activities. When 
expressing FOXO3, ER-positive cells show decreased levels of expression of several ER-
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regulated genes, including those involved in cell growth and proliferation. Over-expression of 
FOXO3 in vivo has also been shown to suppress E2-induced tumorigenesis (138). Investigations 
into patient survival have found that elevated levels of FOXO3 is significantly correlated with 
long-term patient survival, and that FOXO3 expression can be utilized as a favorable prognostic 
indicator of overall breast cancer patient survival (139). 
When FOXO3 is inhibited, an opposite effect is observed, with tumorigenesis being 
promoted. As mentioned previously, S644 of FOXO3 can be phosphorylated by IKKb, leading to 
its polyubiquitination, and subsequent degradation. This decrease in FOXO3 nuclear activity, is 
shown to correlate with poor survival in breast cancer (110). 
While there is very strong support for FOXO’s role as a tumor suppressor, a converse 
relationship in which FOXO3 actually acts to promote tumor progression, has been observed. In 
one study, cancer cells undergoing serum starvation showed increased localization of FOXO3 to 
the nucleus, and a corresponding upregulation of the matrix metallopeptides (MMP) MMP-9 and 
MMP-13. When active, MMPs degrade the extracellular matrix (ECM), resulting in an increase 
in cell invasion. Increased cancer cell invasion was observed in the serum starved breast cancer 
cells (140). Building on this, it has been found that constitutively nuclear, and thereby 
constitutively active, FOXO3 can lead to poorer prognosis in breast cancer patients, and an 
enhance hyperactivation of the PI3K/AKT signaling pathway (141). More specifically, this 
sustained FOXO3 activity has been linked to increased lymph nodal metastasis in invasive ductal 
carcinoma (IDC) (142). 
FOXO3 must be active within a certain range to be most effective in its role as a tumor 
suppressor, too little or too much activity and FOXO3 leads to cancer progression and poor 
prognosis. These contradictory roles FOXO3 plays in cancer development, both suppressing and 
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promoting tumorigenesis, highlight the need for a greater understanding of the mechanisms 
through which FOXO3 activity is regulated.  
1.5 SIGNIFICANCE AND PUBLIC HEALTH RELEVANCE 
Breast cancer is the most commonly occurring cancer in US women, with 1 in 8 women 
developing an invasive breast cancer in her lifetime. While there have been extraordinary steps 
made in the development and of targeted therapies, breast cancer is still the second leading cause 
of cancer related death in US woman (1). There are still thousands for whom current therapies do 
not work, or lose their efficiencies (143). A greater understanding of cancer development and 
progression is essential to finding new ways to identify and target the drivers of cancer 
development and progression. One such avenue down which to explore, is oxidative stress. 
Elevated levels of oxidative stress in a major risk factor in breast cancer, and it’s been found that 
post-menopausal women, who are generally at increased risk for breast cancer development, also 
show increased markers for oxidative stress (144). Unfortunately, antioxidant therapies have 
proven ineffectual. If we can gain a deeper understand of how these oxidative stress induced 
redox-signaling pathways work, it is possible to develop more effective therapies for those at-
risk patients for whom therapies fail. 
In this dissertation, we define the mechanism by which oxidative stress and the 
antioxidant enzyme PRDX1 regulates the activity of the tumor suppressor FOXO3, and the effect 
such regulation has on FOXO3 downstream transcriptional targets. Such a mechanism is novel, 
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giving us a deeper understanding of transcriptional regulation through oxidative stress and redox 
signaling. 
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2.0  MATERIALS AND METHODS 
*This chapter has been partially published in Antioxidants & Redox Signaling (145)  and 
permission has been obtained from the journal regarding the copy-right. ARS correspondence: 
Karen Ballen (KBallen@liebertpub.com) 
2.1 CELL CULTURE 
HEK 293T (293T) and HeLa cells were obtained from ATCC. These cells were grown in 
DMEM (Mediatech) supplied with 10% heat-inactivated FBS (HyClone), 100 units/ml penicillin, 
100 mg/ml streptomycin (Mediatech) and 2 mM l-glutamine (Mediatech) (complete DMEM) in a 
37° C incubator supplied with 5% CO2. Prdx1+/+ and Prdx1-/- MEFs were generated as described 
in (78) from Prdx1 knockout and parental mice (82) and grown in the same conditions as the 
293T. Except when otherwise stated, chemicals used were obtained from Sigma. 
2.2 PLASMIDS 
pcDNA3-FLAG, pcDNA3-FLAG-HA, pcDNA3-FLAG-FOXO3 and pcDNA3-FLAG-HA-
FOXO3 have previously been described (146). Site-directed mutagenesis of FOXO3 plasmids 
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were performed using Stratagene’s QuickChange II XL kit (Agilent Technologies) following the 
manufacturer’s guidelines. The oligonucleotides used were designed using the online 
QuickChange Primer design application (Agilent Technologies) and were synthesized from 
Integrated DNA Technologies. The pcDNA3-FLAG-HA-FOXO3 plasmid was used as a 
template to generate all five single C-to-S mutants. Each clone obtained was sequenced with four 
different sequencing primers to span, with overlaps, the entire coding sequence. To generate the 
double, quadruple and quintuple C-to-S mutants, newly synthesized single Cys-to-Ser mutants 
were used as templates for successive mutagenesis rounds with full-length sequencing after each 
round. To generate the Cys-to-Ser mutants of pcDNA3-FLAG-FOXO3, the inserts of the several 
C-to-S mutants of pcDNA3-FLAG-HA-FOXO3 were excised with a BamH1-Xho1 (New 
England Biolabs) restriction enzyme digestion and cloned into the pcDNA3-FLAG-FOXO3 
plasmid, also digested with BamH1 and Xho1 to remove the un-mutated FOXO3 insert. shRNA 
for FOXO3 (NM_001455.x-2766s1c1 clone) was purchased from Sigma. shPRDX1 expression 
constructs were used as previously described (91). 
2.3 FOXO3 – H2O2 DOSAGE  
HEK 293T cells (5 x 105) were transiently transfected with 2 µg pcDNA3-FLAG-HA (EV) or 
pcDNA3-FLAG-FOXO3 plasmids, using the Fugene 6 system for 48 hours. Cells were serum 
starved for 30 min, then treated with 0, 25, 100, 250, or 500 µM H2O2 for 30 min. Samples were 
lysed using a tris lysis buffer (50mM Tris; 2% Triton X-100; 0.5 mM EDTA; 0.5 mM EGTA; 
150 mM NaCl; 10% glycerol; 50 mM NaF; 1 mM NaVO4; 40 mM β-glycerophosphate), 
supplemented with 30 µg/ml catalase from bovine liver (Sigma), and proteinase inhibitors. 
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Protein concentrations were quantified using the Pierce BCA Protein Assay kit, according to the 
manufacturer’s instructions (Thermo). 1 mg of cell lysate was incubated with 20 µL of acid 
treated Anti-FLAG M2 Affinity Gel (Sigma) and 400 µL lysis buffer, at 25˚ C for 3 h, with 
rotation. Precipitated samples were collected and washed four times with lysis buffer, and once 
with 1x TBS. Beads were boiled in Laemmli sample buffer (BioRad) in the presence or absence 
of β-mercaptoethanol (Sigma) for 10 min. 20 µg of whole cell lysate input was prepared in 
Laemmli sample buffer as above for 5 min. 
2.4 FOXO3 C-TO-S MUTANTS TRANSFECTION 
HEK 293T cells (5 x 105) were transiently transfected with 2 µg EV, pcDNA3-FLAG-FOXO3, 
or pcDNA-FLAG-HA-FOXO3 constructs containing various C-to-S mutations, using the Fugene 
6 system for 48 h. Cells were serum starved for 30 min, then treated with 0 or 25 µM H2O2. 
Samples were lysed using the tris lysis buffer detailed above, supplemented with 30 µg/ml 
catalase from bovine liver (Sigma), and proteinase inhibitors. Protein concentrations were 
quantified using the BCA protein assay (Thermo). IP of 1000 µg (or 1500 µg for nuclear 
localization) of cell lysate was processed as detailed above. 
2.5 PRDX1 C-TO-S MUTANTS TRANSFECTIONS 
HEK 293T cells (5 x 105) were co-transfected with pcDNA-FLAG-FOXO3 and pcDNA3-HA-
PRDX1 or pcDNA3-HA-PRDX1 constructs containing various C-to-S mutations using the 
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Fugene 6 system for 48 h. Cells were serum starved for 30 min, then treated with 0 or 25 µM 
H2O2. IP samples were prepared as above with 1.5 mg of cell lysate was for relative protein 
quantification.  
2.6 FOXO3-PRDX1 INTERACTION IN MEFS 
Confluent Prdx1+/+ and Prdx1-/- MEFs were serum starved for 30 min then treated with 0, 25, or 
250 µM H2O2 for 30 min. Cells were lysed in the aforementioned tris lysis buffer and 80 µg of 
cell lysate was used for relative protein quantification. 
2.7 WESTERN BLOTTING 
Prepared IP samples and corresponding whole cell lysates were fractionated by SDS-PAGE and 
transferred to a nitrocellulose membrane according to manufacturer (BioRad). Membranes were 
blocked with 5% BSA in TBS for 30 min, and incubated with antibodies against FOXO3 
(1:1000) (Abcam), P-FOXO3 T32 (1:1000) (Cell Signaling), PRDX1 (1:4000) (Abcam), PRDX-
SO3 (1:500) (Abcam), 14-3-3 (1:1000) (Cell Signaling), or actin (1:1000) (Oncogene), overnight 
at 4 °C. Membranes were washed four times for 5 min in TBST (0.05% Tween-20), and 
visualized by IR or chemiluminescent detection. For IR processing, membranes were incubated 
with a 1:15000 dilution of anti-goat, anti-rabbit, or anti-mouse IRDye (LI-COR), for 30 min at 
25˚ C. Blots were washed with TBST 3 times and with TBS once, and imaged on an Odyssey 
(LI-COR) imager. Membranes processed by chemiluminescence were incubated in a 1:10000 
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dilution of HRP-conjugated anti-mouse or anti-rabbit antibodies for 1 h at 25˚ C. Blots were 
washed four times with TBST for 5 min, and exposed to ECL for 1 min.  
2.8 FOXO3 NUCLEAR LOCALIZATION IN 293T CELLS 
Nuclear localization of 5.0 x 104 293T cells transiently transfected with Fugene 6 for 24 h with 
50 ng EGFP-FOXO3 or FOXO3-EGFP C31S or C150S mutants, transferred to complete media 
for 24 h, serum starved for 1 h, then treated with 100 µM H2O2 or vehicle and 20 µM LY294002 
or vehicle for 30 min, and fixed with 2% paraformaldehyde for 15 min was quantified by blinded 
scoring of triplicate images from three separate experiments using a IX83 microscope 
(Olympus). 
2.9 FOXO LUCIFERASE ASSAY 
FOXO signaling activity was quantified in mouse embryonic fibroblasts or HEK 293T cells 
utilizing the dual-luciferase Cignal FOXO Luciferase Reporter assay (Qiagen). 2.5 x105 MEFs 
were transiently co-transfected with 350 ng Cignal reporter plasmids, 0.5 µg of PRDX1 and 
FOXO3 or FOXO3 cysteine mutant plasmids and compared to FOXO3 plus vector control 
samples. Transfections were performed with Fugene 6 for 24 h. Luciferase activity was 
normalized to the internal Renilla control. The effect of oxidative stress on FOXO3 activity was 
quantified in 293T cells by transfection with 350 ng Cignal reporter plasmid, 50 ng FOXO3 or 
the FOXO cysteine mutants. 500 ng PRDX1 was transfected into the cells 8 h later and incubated 
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for an additional 14 h Luciferase activity was measured 1.5 h following 30 min 0 to 250 µM 
H2O2 treatment. Dual luciferase activity was measured in 1x passive lysis buffer using the 
manufacturer’s protocol (Promega).  
2.10 ENDOGENOUS TRANSCRIPT QUANTIFICATION IN 293T CELLS 
HEK 293T cells (2.5 x 105) infected with pLKO.1 control or shPRDX1 plasmids were serum 
starved for 1 h then treated with 0 or 250 µM H2O2 for 16 h. RNA was isolated utilizing the 
GeneJET RNA Purification Kit (Thermo Scientific) and converted to cDNA with the qScript 
cDNA synthesis kit (Quanta Biosciences). SESN3, P27, BIM, SOD2, CAT and P21 transcripts 
were quantified by SYBR green real-time PCR (BioRad) relative to YWHAZ control using 
custom primers (Table 2.1) and accounting for PCR efficiency. 
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Table 2.1: qPCR primers for endogenous transcript quantification. 

















2.11 QUANTITATIVE RT-QPCR 
Cell lysates were generated with the Cells-to-CTkit (Life Technologies). RT enzyme, individual 
Taqman assays and all PCR enzymes, dyes and buffers were purchased from Life Technologies 
and used according to the manufacturer's suggestions. All qPCRs were run on an ABI 7900HT 
instrument.  
2.12 CELL VIABILITY ASSAY 
HEK 293T cells (5 x 105) were transiently transfected with 2 µg pcDNA3-FLAG-FOXO3 
plasmids, using the Fugene 6 system for 24 h. Cells were then trypsinized, and then 2x104 cells 
were plated into the wells of a 96-well assay plate. The next day, the cells were treated with 0, 
250, or 500 µM H2O2 for 3 h. Viability, cytotoxicity, and apoptosis were then measured using 
the ApoTox-Glo Triplex Assay (Promega), following the manufacturer’s protocol.   
2.13 WOUND HEALING ASSAY 
One million MDA-MB-453 cells were infected with a pLKO.1 shPRDX1 or control construct 
then transfected in a 12-well plate with 25 nM let-7 miRIDIAN microRNA hairpin inhibitor (GE 
Dharmacon) or miRIDIAN microRNA hairpin inhibitor negative control #1 (GE Dharmacon)  
and 25 nM siGLO Green Transfection Indicator (GE Dharmacon) utilizing 5 μl DharmaFECT 2 
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transfection reagent (GE Dharmacon) per well. Confluent cultures were scratched with a 10 μl 
pipette tip in the presence of mitomycin C and photographed after 48 h to measure wound 
healing. Wound area was quantified with the Image J plugin MRI Wound Healing Tool (Volker 
Bäcker). let-7b expression was used as an indicator of let-7 inhibition. The relative wound area 
was compared in PRDX1-deficient cells and control cells treated with the let-7 miRIDIAN 
inhibitor normalized to control microRNA hairpin inhibitor. Average values were compared 
from 4 separate experiments + SEM.  
2.14 CHIP ASSAY 
293T cells were seeded (4 x 106 cells/dish 150mm) and 24 h later transfected with EGFP-FOXO3 
plasmid (14 µg/dish) by Calcium Phosphate method. 48 h after transfection complete medium 
was replaced with serum-free medium for 30 min, followed by H2O2 (100 µM) treatment for 30 
min. Cells were cross-linked with 1 % formaldehyde for 10 min at 25˚ C, then the reaction was 
stopped by addition of glycine to a final concentration of 0.125 M. Cross-linked chromatin was 
immunoprecipitated with 1 µg of FOXO3 antibody (ab12162 Abcam) as previously described 
(147). The genomic regions in the host gene and intronic promoter, close to FOXO3 binding 
sites, were amplified with primers designed by the Primer-Blast NCBI software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The following primer sequences were used: 
MIR99HG oligo#1 FW: 5'-CTATGCGCCACTCTGTGCAA-3'; MIR99HG oligo#1 RV: 5'-
CTAATTACCGCGCACAAGCTG-3'; let-7c intronic prom oligo #2 FW: 
5'GGCATAAACCCGTAGATCCG-3'; let-7c intronic prom oligo #2 RV: 5'-
GAGCTTGTGCGGTCCACTT-3. Quantification of cDNA was performed in triplicate on an 
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Applied Biosystems 7500 Real-Time PCR System SDS v1,2, using the SYBR green dye 
detection method. ChIP assay results were evaluated by the double delta CT method.  
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3.0  A PEROXIDASE PEROXIREDOXIN 1-SPECIFIC REDOX REGULATION OF 
THE NOVEL FOXO3 MIRORNA TARGET LET-7 
*This chapter has been partially published in Antioxidants & Redox Signaling (145)  and 
permission has been obtained from the journal regarding the copy-right. ARS correspondence: 
Karen Ballen (KBallen@liebertpub.com) 
3.1 INTRODUCTION 
Appropriate cell responses to stress are necessary to decide cell fate. Recent evidence establishes 
protein sulfhydryl groups as modulators of signaling events through oxidation state changes, 
which impact protein interactions and activity (148). This post-translational calibration requires a 
dynamic reversibility of the protein modification. Interestingly, in contrast to 
(de)/phosphorylation events induced by the interplay of protein kinases and phosphatases, 
protein sulfhydryl group oxidation to highly oxidized forms such as sulfonic acid can be 
irreversible, resulting in protein degradation or in the case of peroxiredoxins, a change of 
function. Peroxiredoxin (PRDX) family members (typical 2-Cys: PRDX1-4, atypical 2-Cys: 
PRDX5 and 1-Cys: PRDX6) are antioxidant enzymes that reduce peroxides via catalytic cysteine 
oxidation to sulfenic acid.  Evidence is accumulating that demonstrates 2-Cys PRDXs as 
important redox sensors in signaling (68) through two unique features: a) a highly reactive 
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catalytic cysteine that converts to a protein sulfenic acid moiety that produces a disulfide bond 
with a resolving cysteine, which can be reduced via thioredoxin to reset catalytic function (66); 
and b) during recycling the catalytic cysteine of PRDX can be further oxidized, which promotes 
formation of PRDX decamers that display chaperone functionality, but lack peroxidase activity 
(68). These features equip PRDX1 to sense and react to changes in redox signaling accordingly 
by controlling protein-binding partners. For example, we have recently shown heightened 
oxidative stress can over-oxidize PRDX1, which causes PRDX1 to dissociate from MKP1 as 
well as increase association and activity of MKP5 thereby regulating senescence (91). A similar 
mechanism has been described for PRDX1 and PTEN (78) or MST1 (79) and for PRDX2 and 
ERp46 (149). Recently, PRDXs have gained attention to act as redox-relays involving the 
catalytic and resolving cysteine to form disulfides with the partnering protein to transfer 
oxidative equivalents. This has been suggested for PRDX1 and ASK1 (150,151) and most 
recently, a transient PRDX2-STAT3 redox-relay has been described that resulted in STAT3 
oligomerization and inactivation (152).  
Our studies shown here demonstrate that PRDX1 interacts with the transcription factor 
FOXO3 through disulfide bonds. The mammalian forkhead box transcription factors of the O 
class (FOXOs) comprises of four family members (FOXO1, 3, 4 and 6) that are highly related 
tumor suppressors that provide resistance to oxidative stress, halt cell cycle progression, and 
control the induction of cellular apoptosis. Although FOXOs serve as major cellular ROS 
arbitrators (153), the mechanisms by which FOXOs sense and integrate ROS signals to define 
transcriptional outcomes are still poorly understood (154). A recent mass spectrometry analysis 
indicated FOXO cysteines to be involved in protein binding underscoring its role for redox-
sensing (93). In response to oxidative stress, FOXO proteins translocate to the nucleus due to 
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phosphorylation by mammalian Sterile 20-like kinase 1 (MST1) and Jun N-terminal kinase 
(JNK) as well monoubiquitination (96). FOXO is negatively regulated through the 
phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, which promotes cytoplasmic 
sequestration of FOXO via AKT-induced phosphorylation and therefore causing FOXO-
inactivation in many cancers (96,155).  
As cancer cells carry a higher pro-oxidant burden compared to normal cells (156), we 
examined the role of PRDX1 in FOXO3 function and binding under pro-oxidant conditions. We 
establish that PRDX1 binds FOXO3 under H2O2 stress and regulates FOXO3 nuclear 
localization and activity through disulfide bridges involving the PRDX1 peroxidatic C52 and 
resolving C173 and surprisingly C71, which has not been previously seen. Within FOXO3, 
PRDX1-binding engages C31 and 150, the latter of which is not conserved among FOXO family 
members. Mutation of these FOXO3 cysteines cause changes to the phosphorylation levels of 
AKT substrate sites and heightened cytoplasmic localization that is responsive to PI3K inhibition 
in comparison to FOXO3WT. We also demonstrate for the first time that let-7c, a member of the 
let-7 family of microRNAs (miRNA) first identified in the nematode C. elegans as regulators of 
development, and widely regarded as a tumor suppressor miRNA, is a novel FOXO3 target. let-
7c and let-7b miRNAs are significantly increased by H2O2 exposure in a FOXO3 and PRDX1-
dependent manner, and inhibit breast cancer cell migration. Notably, several functional and 
mechanistic parallels exist for FOXO proteins and let-7. Both mediate tumor suppression and 
glucose homeostasis (157) and expression of the let-7 miRNA family has similarly been shown 
to be governed by various ROS-inducing stressors (158,159). Importantly, loss of let-7c 
expression in cancer cells promotes migration and invasion (160,161). Taken together, these data 
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provide compelling evidence for an existence of a redox-specific signaling axis comprised of 
PRDX1, FOXO3 and let-7c miRNAs in regulating oxidative stress signaling in breast cancer.  
3.2 RESULTS 
3.2.1 PRDX1 interacts with FOXO3 and regulates its nuclear function 
We confirmed a PRDX1 FOXO3 interaction by precipitating endogenous FOXO3 bound to 
PRDX1 by immunoblot (Figure 3.1). Precipitation of FLAG-FOXO3 from transfected 293T cells 
indicated PRDX1 binding was elevated following treatment with 25 to 500 μM H2O2 in the 
presence of lysis buffer containing N-ethylmaleimide (NEM), a chemical agent that alkylates the 
thiol group on cysteines, therefore reducing post-lysis oxidation events that might otherwise 
occur (Figure 3.2).  Interestingly, the PRDX1-FOXO3 complex displayed time-dependent 
binding dynamics when transfected 293T cells were treated with 250 and 500 μM H2O2 (Figure 
3.3). Maximal PRDX1-FOXO3 oligomerization was seen at 30 min, which returned to baseline 
after 3 hrs. An assay to measure apoptosis, cell viability, and cytotoxicity found no significant 
changes in any of the three measurements, between treatment and no treatment over a period of 3 
h, suggesting that the decrease in PRDX1-FOXO3 binding was not a result of cell death (Figure 
3.4). Further experiments in the absence of NEM found that binding dynamics of FLAG-FOXO3 
and PRDX1 followed a U-shaped H2O2 dose curve with maximal binding at 100 μM H2O2 and 
complex dissociation at higher concentrations (Figure 3.5). In addition, we could not detect any 
over-oxidized PRDX1 binding to FOXO3, suggesting that PRDX1 over-oxidation on its catalytic 





Figure 3.1: PRDX1 endogenously binds to FOXO3. 
Immunoprecipitation of pre-cleared lysate with PRDX1 or IgG antibodies found PRDX1 bound-FOXO3. 
293T cells underwent serum starvation for 30 min and were then treated with the 0 or 100 μM H2O2 for 




Figure 3.2: PRDX1 binds to FOXO3 in presence of H2O2. 
293T cells were transfected with pcDNA3-FLAG-FOXO3A or EV and treated with increasing 
concentrations of H2O2 for the indicated times. Prior to lysis, cells were washed with 20 µM N-
ethylmaleimide (NEM) in PBS to block lysis-induced disulfide bond formation. FLAG-labelled proteins 













Figure 3.3: PRDX1 binds to FOXO3 in H2O2 time dependent manner. 
293T cells were transfected with pcDNA3-FLAG-FOXO3A or EV and treated with the indicated 
concentrations of H2O2 for increasing periods of time. Prior to lysis, cells were washed with 20 µM N-
ethylmaleimide (NEM) in PBS to block lysis-induced disulfide bond formation. FLAG-labelled proteins 









Figure 3.4: Changes in PRDX1-FOXO3 binding are not a result of cell death. 
293T cells were transfected with FLAG-FOXO3 DNA. Cells were treated with H2O2 as indicated 
for 3 h. Apoptosis, cell viability, and cell cytotoxicity were measured using the Promega 





Figure 3.5: Over-oxidation of PRDX1 leads to FOXO3 release. 
293T cells were co-transfected with FLAG-FOXO3. Before lysis, cells were treated with H2O2 as 
indicated for 30min. Cells were lysed with lysis buffer NOT containing NEM. Co-IPs were performed 
using anti-FLAG coated beads and Co-IPs were resolved under reducing conditions, followed by 








To investigate if PRDX1 binding to FOXO3 has a functional impact, we assessed 
FOXO3 nuclear translocation in Prdx1-/- and Prdx1+/+ MEFs. Interestingly, MEFs lacking 
PRDX1 displayed primarily nuclear FOXO3 localization in contrast to wild-type MEFs 
expressing PRDX1 (Figure 3.6). Given the low transfection efficiency of MEFs, we next utilized 
293T cells with reduced PRDX1 expression transfected with a FOXO3-EGFP reporter construct 
(Figure 3.7). As Figure 3.8 shows, FOXO3 nuclear localization was significantly increased in 
293T cells harboring 90% less PRDX1, suggesting PRDX1 deterred FOXO3 nuclear 
translocation. Investigating the role of PRDX1 on FOXO3 function further, we next evaluated 
FOXO3 activity specifically using a dual-luciferase reporter assay in Prdx1-/- MEFs transiently 
transfected with FOXO3 and/or PRDX1. As expected, PRDX1 decreased luciferase signals by 
50% (Figure 3.9). Investigating FOXO3 target gene expression by qPCR showed that PRDX1 
knockdown increased expression of several FOXO3 targets in H2O2 treated 293T cells compared 





Figure 3.6: Absence of PRDX1 results in FOXO3 nuclear localizationin MEFs. 
Representative pictures of Prdx1+/+ MEFs and Prdx1-/- MEFs nucleofected with pcDNA3-
FLAG-FOXO3 WT for 48 hours followed by fixation and analysis by IF with anti-FLAG 






Figure 3.7: PRDX1 knockdown in 293T cells. 
(A) PRDX1 protein expression following lentiviral infection with shPRDX1 compared to EV in 293T 






Figure 3.8: Enhanced FOXO3 nuclear localization in PRDX1 knockdown cells. 
The percentage of 293T cells displaying nuclear FOXO3-EGFP localization was enhanced with reduction 
of PRDX1; 150 or more cells analyzed per sample, p < 0.0001 (t-test). Cells infected with shPRDX1A or 
control lentivirus for 48 h, followed by transfection with FOXO3-EGFP for 24 h. H2O2 was added during 




Figure 3.9: PRDX1 decreases FOXO3 activity. 
HA-PRDX reduced FLAG-FOXO3 activity when transiently co-transfected into MEF and analyzed 
utilizing a dual luciferase reporter assay. Values (mean + SE) were normalized to vehicle treatment. *p < 
















Figure 3.10: FOXO3 target expression increases following PRDX1 knockdown. 
qPCR gene transcription of SESN3 and P27 was increased in PRDX1-deficient 293T cells (white bars) 
treated with 250 µM H2O2 compared to pLKO.1 control cells (black bars) after 16 h. Values (mean + SE) 










3.3 PRDX1 AND FOXO3 ASSOCIATE THROUGH DISULFIDE BONDS 
Typical 2-Cys peroxiredoxins and FOXO proteins have been suggested to form disulfide bonds 
with target proteins (93). We explored whether covalent cysteine disulfide bridges exist between 
PRDX1 and FOXO3. Five cysteines are present in FOXO3 at positions 31, 150, 190, 362 and 
622, while PRDX1 has 4 cysteines at positions 52, 71, 83 and 173. To investigate possible 
disulfide bridge interactions between PRDX1 and FOXO3, we analyzed Prdx1+/+ and Prdx1-/- 
MEFs using two-color infrared (IR) antibody detection and identified one band staining positive 
for both PRDX1 and FOXO3 around 140 kDa after H2O2 treatment (Figure 3.11), which was 
reduced when lysates were treated with β-ME. This suggests an oligomeric PRDX1-FOXO3 
protein complex composed of monomeric FOXO3 (90 kDa) disulfide bound to dimeric PRDX1 
(2x 23 kDa). To gain further insight into the specific cysteines responsible for the PRDX1-
FOXO3 interaction, co-immunoprecipitations (co-IPs) of endogenous PRDX1 with FLAG-
FOXO3 single cysteine mutants revealed that loss of FOXO3 C31 or C150 decreased binding to 
PRDX1 (Figure 3.12). Conversely, co-precipitating endogenous FOXO3 with HA-PRDX1 single 
cysteine mutants showed that PRDX1 C52, C71 or C173 mutants decreased binding of 
endogenous FOXO3 as well (Figure 3.13). PRDX1 C71 has yet to be described to play a role in 
PRDX1 protein associations. Additionally, disulfide-dependent complex formation was further 
analyzed and demonstrated that, as shown in Figure 3.12, while H2O2 treatment induced 
endogenous PRDX1 binding to wild-type FLAG-FOXO3, and decreased PRDX1 binding to C31 
and C150 single mutants, the FLAG-FOXO3 double mutant (C31,150S) and the quintuple 




Figure 3.11: PRDX1 and FOXO3 form an oligomer via disulfide bonds. 
A PRDX1-FOXO3 complex was detected under nonreducing conditions in Prdx1+/+, but not Prdx1-/- MEFs, when treated with 
the indicated concentrations of H2O2 for 30 min by immunoblot with two-color IR antibody detection.  
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Figure 3.12: FOXO3 C31 and C150 are involved in binding to PRDX1. 
Anti-FLAG IP of 293T cells transfected with EV or FLAG-FOXO3 (WT or single C-to-S mutants) 
displayed reduced PRDX1 binding to FOXO3 C31S or C150S when treated with H2O2 for 30 min by 
immunoblot. 
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Figure 3.13: PRDX1 C52, C71 and C173 are involved in binding to FOXO3. 
Anti-HA IP of 293T cells transfected with EV or HA-PRDX1 (WT or C-to-S mutants) showed reduced 
FOXO3 binding with PRDX1 C52S, C71S, or C173S mutants when treated with H2O2 for 30 min (*HA-
PRDX1). 
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(C∆S), showed no PRDX1 binding (Figure 3.14). To further examine the importance of 
FOXO3 C31 and C150 in oligomeric formation, we expressed FLAG-FOXO3WT, C31S and 
C150S in 293T cells. Figure 3.15 shows the FOXO3-PRDX1 oligomer can be detected with 
wild-type FLAG-FOXO3, but not with single cysteine FOXO3 mutants. As FOXO3C31 and 
FOXOC150 are important for PRDX1 binding, we next examined how cysteine mutant FOXO3 
activities were responding to PRDX1 mediated decrease under H2O2-induced stress. Using a 
dual-luciferase reporter assay we observed that under lower H2O2 treatments PRDX1 is able to 
decrease FOXO3 activity significantly, and under higher H2O2 doses (250 µM), PRDX1-induced 
decrease of FOXO3 was abrogated (Figure 3.16A). Additionally, PRDX1 did not further 
decrease FOXO3 C31 or C150 activity, nor did higher H2O2 doses increase mutant activity 
(Figures 3.16B and 3.16C). In contrast to wild-type FOXO3, PRDX1 was unable to lower 
FOXO3 (∆C) luciferase activity (Figure 3.17).  
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Figure 3.14: FOXO3 C31, 150S double mutant cannot bind to PRDX1. 
Mutation of FOXO3 cysteines reduced PRDX1 binding when treated with 25 µM H2O2 for 30 min. Anti-
FLAG IP of 293T cells transfected with EV or FLAG-FOXO3 (WT, C31S, C150S, C31,150S double 
mutant, or ∆Cys mutants) was detected by immunoblot. 
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Figure 3.15: FOXO3 C31 and C150 mutants do not form the PDX1-FOXO3 oligomer. 
A PRDX1-FOXO3 complex was detected in FLAG-FOXO3 WT, but not C31S or C150S mutant Anti-
FLAG samples under nonreducing conditions in 293T cells co-transfected with FLAG-FOXO3 constructs 
and HA-PRDX1 treated with 25 µM H2O2 for 30 min. 
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Figure 3.16: Effect of PRDX1 on FOXO3 C31S and C150S mutant activity. 
The ability of PRDX1 to reduce FOXO3 activity was inhibited with H2O2 treatment in 293T cells in (A) FOXO3 WT, but not (B) C31S or 
(C) C150S mutants. Cells were transiently transfected with FOXO3 and PRDX1 constructs in a dual-luciferase assay treated with 0–250







Figure 3.17: PRDX1 decreases FOXO3 activity via cysteine interactions. 
HA-PRDX reduced FLAG-FOXO3 activity, but not FLAG-FOXO3 ∆Cys, when transiently co-
transfected into MEF and analyzed utilizing a dual-luciferase reporter assay. Values (mean + SE) were 






3.4 FOXO3 DISULFIDE BONDING WITH PRDX1 DETERMINES SUBCELLULAR 
LOCALIZATION UNDER H2O2 STRESS 
Several lines of evidence demonstrate that FOXO proteins translocate to the nucleus under 
increased levels of ROS, reviewed in (162). Importantly, nuclear localization of FOXO proteins 
is a pre-requisite for their transcriptional activity, as such FOXOs are highly regulated through 
mechanisms that alter nucleo-cytoplasmic shuttling (154). To address if the PRDX1-FOXO3 
disulfide bound complex influences FOXO3 protein nuclear localization, we expressed WT-, 
C31S- or C150S-FOXO3-EGFP reporter constructs in 293T cells and quantified nuclear 
localization following H2O2 exposure for one hour. Figure 3.18 shows that unlike WT FOXO3, 
C31S- and C150S-mutant FOXO3s fail to translocate to the nucleus, even during high dose H2O2 
treatment. These data indicate that FOXO3 C31 and C150 regulate FOXO3 nuclear 
translocation. A well-known mechanism regulating FOXO3 nuclear localization is 
phosphorylation on T32 by AKT, which sequesters FOXO3 in the cytosol (118). We therefore 
examined the AKT phosphorylation status of C31S and C150S FOXO3 mutants. Figure 3.19A 
shows FOXO3 WT T32 phosphorylation levels were increasing following treatment with H2O2, 
which corresponded with binding of 14-3-3 to the PRDX1-FOXO3 complex (Figure 3.20). 
Interestingly, both mutants showed increased basal levels of T32 phosphorylation compared to 
FOXO3 WT, with phosphorylation further increasing with additional H2O2 treatment. We also 
examined phosphorylation at S318, another AKT phosphorylation site known to enhance 
FOXO3 nuclear export (163), and found no change in phosphorylation levels between FOXO3 
WT, and the C31S, and C150S single FOXO3 mutants (Figure 3.19B), suggesting the 
binding of PRDX1 to FOXO3 has a site-specific effect on FOXO3 phosphorylation. Given that 
FOXO3 WT, and the C31S, and C150S single FOXO3 mutants (Figure 3.19B), suggesting the 
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binding of PRDX1 to FOXO3 has a site-specific effect on FOXO3 phosphorylation. Given that 
FOXO3 C31S and C150S mutants have increased T32 phosphorylation and dysfunctional 
translocation in response to high doses of H2O2 (Figure 3.18 and 3.19A), we questioned if PI3K 
inhibition is capable of promoting FOXO3 C31S and C150S mutant nuclear translocation. To do 
so, we applied experimental conditions that would decrease the activation of kinases such as 
STK4/MST1, JNK and p38 (82,106) known to induce FOXO3 nuclear localization by 
phosphorylating FOXO3. For example, MST1 phosphorylation on FOXO3 is known to 
overcome its AKT-induced cytoplasmic retention by decreasing 14-3-3 binding to FOXO3 (82). 
EGFP-FOXO3 localization was compared in 293T cells treated with 100 µM H2O2 for 30 min. 
Under this treatment 14-3-3 binding to FOXO3 was not decreased (Figure 3.20). In addition, as 
FOXO3 nuclear localization is dependent on DNA concentration (Table 3.1), we assessed EGFP-
FOXO3 localization of 50 ng of EGFP-FOXO3 in a sub-confluent population cells to ensure 
AKT activity towards FOXO3 (164). We found that 293T cells were transfected with indicated 
concentration of EGFP–FOXO3 WT DNA for 24 hours, then transferred to complete media for 
an additional 24 hours. FOXO3 localization was then scored as either nuclear, cytoplasmic, or 












Figure 3.18: Disulfide bonds between PRDX1 and FOXO3 modulate FOXO3 subcellular localization. 
(A) 30 min of H2O2 treatment enhanced nuclear EGFP-FOXO3 content in WT, but not C31 or C150 mutant constructs, 48 h following 








Figure 3.19: PRDX1 binding differentially modulates FOXO3 phosphorylation. 
293T cells transfected with FLAG-FOXO3 (WT, C31, or C150 mutants) were treated with H2O2 and 
immunoblotted for FOXO3 Phospho-T32, FOXO3 Phospho-S318, FOXO3 and Actin. (A) T32 
phosphorylation of FOXO3 C31S or C150S was heightened under basal conditions compared to FOXO3 
WT. (B) S318 phosphorylation of FOXO3 WT, C31S and C150S was unaffected by H2O2 treatment. 
Phospho-T32 and Phospho-318 signals were normalized to total FOXO3. Values represent mean + SD 








Figure 3.20: 14-3-3 binding increases with H2O2 concentration. 
293T cells were co-transfected with FLAG-FOXO3. Prior to lysis, cells were treated with H2O2 as 
indicated for 30 min. Co-IPs were performed using anti-FLAG coated beads and Co-IPs were resolved 
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LY294002 (PI3K inhibitor) treatment significantly increased nuclear localization by 
5.7%, 11.7% and 25% in FOXO3WT, FOXOC31S and FOXOC150C, respectively, compared to 
untreated cells (Figure 3.21). These results suggest again that AKT-induced phosphorylation of 
FOXO3 sequesters FOXO3 cysteine mutants in the cytosol. 
3.4.1 Loss of PRDX1 enhances FOXO3 dependent H2O2-induced let-7 miRNA up-
regulation 
As prior studies have reported, increased let-7 family member expression is induced by ionizing 
radiation, genotoxic stress and peroxide (158,159). In C. elegans, let-7 family members have 
overlapping functions with FOXO proteins to regulate development, aging, glucose metabolism, 
stress responses, and act as tumor suppressors (165). We were interested to examine if let-7 
miRNAs are regulated by FOXO3 under oxidative stress. Using the UCSC Genome Browser we 
analyzed the 5’ UTR of let-7b and let-7c in several species for putative FOXO3 binding 
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sequences (YTXXACA) (166). As shown in Figure 3.22, FOXO3 binding sites are preserved in 
the 5’ UTR of MIRLET7B and MIRLET7C.  
To confirm let-7 miRNAs as a potential novel FOXO3 target, we established that H2O2 
treatment of HeLa cells enhanced the expression of both let-7b and let-7c miRNAs (Figure 3.23).  
To determine if FOXO3 is involved in H2O2-mediated enhanced expression of let-7b and let-7c 
in HeLa cells, we performed either an over-expression or a shRNA-mediated knockdown of 
FOXO3 prior to treatment with H2O2. When FOXO3 expression increased, levels of let-7b and 
let-7c were 3-fold and 2-fold higher, respectively (Figure 3.24). As FOXO3 expression was 
significantly diminished, the ability of H2O2 to induce either let-7b or let-7c miRNA expression 
was lost (Figure 3.25). As final confirmation of FOXO3’s role in the H2O2-mediated 
enhancement of let-7 expression, a chromatin IP (ChIP) assay was performed showing that 
FOXO3 binds directly to both of the let-7c promoter regions, the distal host gene and the 
proximal intronic promoter, both considered functional in let-7c transcription (147) (Figure 
3.26). FOXO3 promoter binding was further enhanced following 100µM H2O2 treatment 
compared to no treatment. These data suggested that FOXO3 very likely regulates the expression 
of MIRLET7B and MIRLET7C.  Next, we examined if loss of PRDX1 magnifies let-7 miRNA 
transcription in the context of H2O2 addition. Figures 3.27A and 3.27B show when PRDX1 
expression was more than 90% reduced, let-7b and let-7c expression levels were augmented. 
This effect was further enhanced with 100 µM H2O2 treatment. Moreover, SOD2, an established 
target of FOXO3, was also increased upon H2O2 treatment in the context of PRDX1 knockdown 
(Figure 3.27C). In conclusion, these data suggest that a PRDX1/FOXO3 signaling axis exists that 
directly regulates let-7c expression under H2O2-induced stress. 
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Figure 3.21: AKT-induced phosphorylation of FOXO3 sequesters FOXO3 cysteine mutants in the 
cytosol. 
PI3K inhibition with 20 µM LY294002 enhanced nuclear FOXO3-EGFP WT, C1S, or C2S mutants in 
transiently transfected 293T cells after 24 h. Values represent mean + SE (N= 3) with 150–400 cells 
counted per sample by fluorescence microscopy. Experiment was repeated twice. (B) Representative 
pictures of (A). 
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Figure 3.22: FOXO3 consensus binding sequence found in let-7b and let-7c promoter region. 
(A) Putative FOXO3 binding sequence. (B) Putative FOXO binding motifs in forward and reverse are 
located in the 5` UTR of let-7b and -7c in several species. The consensus FOXO binding sequences in the 
WebLogo (black boxes) are indicated. Numbering is relative to the transcription start site obtained 




Figure 3.23: H2O2 enhances let-7b and let-7c miRNA expression. 
HeLa cells treated with or without 500 µM H2O2 for 18 h were harvested, lysed and analyzed for let- 7b 
and let-7c expression by individual Taqman microRNA expression assays using the delta CT method with 





Figure 3.24: FOXO3 enhances let-7b and let-7c miRNA expression. 
(A) Overexpression of FLAG-FOXO3 enhanced let-7b and c transcription in Hela cells 48 h after 
transfection. Cells were harvested, lysed, and analyzed for miRNA expression by TaqMan assays, using 
the delta CT method with mir-30c as the internal standard. (B) Representative western blot of cell lysis 












Figure 3.25: FOXO3 is required or H2O2 induced let-7b and let-7c miRNA expression. 
(A-B) FOXO3-deficient HeLa cells were nonresponsive to H2O2 treatment. 30 h following transfection of shGFP or shFOXO3, cells were 
treated with or without H2O2 for 18h. Expression profiles of let-7b and let-7c were assessed by individual TaqMan assays with U18 as the 






Figure 3.26: ChIP assays of FOXO3 binding to let-7c promoter region. 
ChIP assays indicate transfected FLAG-FOXO3 binds to the MIR99AHG and intronic let-7c promoter regions and is enhanced following 
100 µM H2O2 treatment for 30 min in 293T cells. Quantification of immunoprecipitated DNA was performed in triplicate by quantitative 
PCR and evaluated by the delta CT method. Values of each immunoprecipitated sample are expressed as a percentage relative to their 













Figure 3.27: Loss of PRDX1 magnifies H2O2 induced let-7b and let-7c miRNA expression. 
(A) let-7b, (B) let-7-c, and (C) SOD2 transcription was increased in PRDX1-deficient cells. HeLa cells were transfected with either a 
shGFP or shPRDX1 construct for 56 h, followed by treatment with or without H2O2 for 18 h. HeLa cells were analyzed for gene 





3.4.2 The PRDX1-FOXO3-let-7 axis regulates breast cancer cell migration 
Lastly, we sought functional confirmation of the PRDX1-FOXO3-let-7 axis. As genetic 
alterations in cancer cells elevate the production of ROS, reviewed in (167) and let-7b and let-7c 
suppress cancer development (165) including breast cancer (168-170), we compared let-7c 
expression levels in normal and breast cancer cases (171). We found let-7c expression to be 
significantly lower in breast cancer tissues compared to normal breast tissue (Figure 3.28). 
FOXO3 showed a similar expression pattern to let-7c, while PRDX1 expression was increased in 
breast cancer compared to normal tissue (Figure 3.29). Comparing changes to PRDX1 and 
FOXO3 expression in normal and breast cancer tissues using Pearson correlation demonstrated 
 
Figure 3.28: Mirlet7 expression in normal and breast cancer tissue. 





Figure 3.29: PRDX1 and FOXO3 expression in normal and breast cancer tissue. 
(A) PRDX1 expression. (B) FOXO3 expression. Data from The Cancer Genome Atlas (TCGA). 
(Courtesy of K. Levine) 
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a significant negative correlation for PRDX1 and FOXO3 in this data set downloaded from GEO 
Accession: GSE62944 (172) (Figure 3.30), suggesting functional significance of our findings. 
This was further substantiated analyzing breast patient cancer survival in data sets from the 
Kaplan Meier Plotter (173) and the Gene Expression-based Outcome for Breast Cancer Online 
(GOBO) (174), which showed that lower expression of FOXO3 as well as higher expression of 
PRDX1 correlate with shortened patient survival (Figure 3.31).  
FOXO3 suppresses cancer development in different ways including the inhibition of cell 
motility (175-180). In contrast, while PRDX1 prevents cancer initiation (87,181), its role in 
cancer is less understood. Interestingly, we have previously shown PRDX1-deficiency in MCF-
10A, MCF-7 and MDA-MB-231 cells increased p38 activation (91), which induces FOXO3 
nuclear localization in MCF-7 cells (106,182). We therefore hypothesized that inhibition of let-
7b and let-7c would affect migration differently in breast cancer cells (MDA-MB-453 or MCF-7) 
with knockdown of PRDX1 (shPRDX1) (Figure 3.32) compared to control vector treatment. 
Intriguingly, cells with reduced PRDX1 showed a 30% increase in let-7 expression (Figure 3.33) 
and a 50% (MDA-MB-453) and a 30% (MCF-7) increased wound closure, respectively when 
transfected with single-stranded RNA oligonucleotide inhibitors that compete with let-7b and let-
7c seed sequences (Figure 3.34). However, when compared with a negative control single-strand 
RNA oligonucleotide, we saw little to no wound closer between the control and the shPRDX1 
cells. Altogether, these data demonstrate a PRDX1 regulated signaling axis exists in breast 







Figure 3.30: Comparing let-7c expression to PRDX1 and FOXO3 expression in normal versus 
breast cancerous tissues. 






Figure 3.31: Patient survival versus PRDX1 and FOXO3 expression levels. 
(A and B) Expression levels of FOXO3 and PRDX1 correlated with relapse free survival (RFS) of breast 
cancer patients from “Gene expression based Outcome for Breast Cancer Online (GOBO)” Fredlund E, et 
al. Breast Cancer Research. 2012;14(4):R113 (C and D) Expression levels of FOXO3 and PRDX1 
correlated with relapse free survival (RFS) of breast cancer patients from “Kaplan Meier Plotter for 




Figure 3.32: PRDX knockdown in breast cancer cell lines. 
PRDX1 protein levels in MDA-MB-453 cells infected with PLKO1-shPRDX1 or EV control. 




Figure 3.33: let-7 expression in PRDX1 knockdown in breast cancer cells. 
EV or shPRDX1 MDA-MB-453 cells were harvested, lysed, and analyzed for miRNA expression by 
TaqMan assays using the delta CT method with U18 as the internal standard (N= 3). 
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Figure 3.34: Wound healing increases following let-7 inhibition in PRDX1 knockdown breast 
cancer cells. 
1 x 106 shPRDX1 (A) MDA-MB-453 or (B) MCF-7 (white bar) cells (white bar) or control cells (black 
bar) were transfected with a let-7 miRNA inhibitor in a 12-well plate and wound healing was assessed 
after 48 h (MDA-MB- 453) or 24 h (MCF-7) in the presence of mitomycin C (0.5 mg/ml). Wound area of 
let-7 inhibitor-treated cells was normalized to control miRNA inhibitor-treated cells (mean + SE) N= 4. 








H2O2 is an important second messenger in cell signaling, where it can directly induce oxidation 
of cysteine sulfhydryl groups in proteins thereby impacting protein activity and facilitate rapid 
signal transfer comparable to other post translational modifications (183). Thus oxidative 
equivalents can be passed on by H2O2-scavenging enzyme such as peroxidases (67). This 
reaction entails a transient disulfide exchange reaction between cysteine thiols, which requires 
close proximity of the peroxidase with a partnering protein (184). Peroxiredoxins have been 
suggested to form disulfide bridges with partnering proteins to pass oxidizing equivalents this 
way, thereby modulating protein activity of their binding partners (150,152). Our data suggests a 
similar mechanism between PRDX1 and the transcription factor FOXO3. As the disulfide 
exchange reaction is transient, capture of stable complexes by co-IP is low as demonstrated by 
weak PRDX1 staining FLAG-FOXO3 pull down experiments despite the high abundance of 
PRDX1 in cell lysate (Figures 3.2 and 3.3).  
FOXO family members have been implicated in ROS signaling involving cysteine thiols. 
For example, a recent study showed p300 to form disulfide reactions with FOXO4 that result in 
its acetylation and nuclear localization (107). However, more examples are needed to fully 
understand specific roles of FOXO proteins in redox response. We present for the first time, 
evidence of an H2O2-dependent regulation of FOXO3 activity directly through the oxidative 
stress-signaling sensor PRDX1. Our data suggest the formation of a disulfide bond between a 
PRDX1-dimer and FOXO3 monomer involving the PRDX1 peroxidatic and resolving cysteines 
C52 and C173, respectively, as well as C71. In FOXO3, the FOXO3 C31 is a shared cysteine 
among FOXO family members, while C150 is unique to FOXO3, suggesting a redox regulation 
that is specific for FOXO3 (Figures 3.11-3.16). We further show the importance of PRDX1-
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FOXO3 binding by demonstrating increased FOXO3 cytoplasmic sequestration (Figure 3.18) 
due to increased AKT phosphorylation of FOXO3 mutants impaired in PRDX1-binding after 
H2O2 treatment (Figures 3.19-3.21). However, a further delineation of the FOXO-PRDX1 
signaling pathway is warranted to determine the role that other family members may play, as a 
recent proteomic profiling report found PRDX1, 2 and 5 are cysteine-dependent binding partners 
of FOXO3 and suggest competition among PRDX family members may be present for FOXO3 
binding (153). 
We show the PRDX1-FOXO3 complex that is formed in the presence of elevated H2O2, 
is a cysteine-dependent oligomer. A unique property to the PRDX1-FOXO3 axis is the 
utilization of C150 of FOXO3, which is exclusive to FOXO3, suggesting specificity of the 
PRDX1-FOXO3 interaction. Mutation of C31 or C150 inhibits FOXO3 complex formation with 
PRDX1 and renders these FOXO3 mutants unresponsive to oxidative insult, exhibiting 
cytoplasmic accumulation, which suggests PRDX1’s binding of FOXO3 via disulfide bonds is 
critical for regulating FOXO3 in response to oxidative stress (Figures 3.11-3.21). Luciferase 
reporter assays indicated FOXO3 becomes unresponsive to PRDX1-induced control following 
treatment with high doses of H2O2 (Figure 3.16), suggesting over-oxidation of PRDX1 impairs 
FOXO3 binding and may also allow FOXO3 post-translational modifications, to induce nuclear 
translocation (Figure 3.8). FOXO3 C31 or C150 mutants (Figure 3.21) were unresponsive to 
PRDX1 regulation, but surprisingly correlated with cytosolic sequestration under H2O2-induced 
stress (Figure 3.18) compared to FOXO3WT. To determine why FOXO3 C31S and C150S 
mutants could not bind PRDX1, but were sequestered from the nucleus (Figure 3.18), the 
phosphorylation status of FOXO3 T32 and S318, which represses FOXO3 through AKT and 
SGK signaling (154), were probed. Interestingly, wild-type FOXO3 showed an H2O2 dependent 
92  
increase in T32 phosphorylation, however, FOXO3 cysteine mutants displayed much higher 
phosphorylation. FOXO3C31S showed an overall higher phosphorylation of T32, while 
FOXO3C150 T32 phosphorylation was higher than FOXO3WT but not as responsive to H2O2 
stimulation (Fig. 3B). Analysis of S318 phosphorylation, however showed no difference between 
wild-type FOXO3 and the FOXO3 cysteine mutants (Figure 3.19B) suggesting that PRDX1 
binding to FOXO3 is site specific, and calibrates T32 phosphorylation, but not S318.  
FOXO3 nuclear localization is regulated by AKT and SGK phosphorylation inducing 14-
3-3 binding and cytoplasmic sequestration or kinases that induce nuclear localization. Candidate 
kinases include MST1, JNK or p38 (106,185) (Figure 3.35) where MST1 can induce nuclear 
localization of an AKT phosphorylated FOXO3 protein (82). Interestingly, all three kinases are 
subject to PRDX1 binding and subsequent regulation, indicating another layer of control in the 
PRDX1/FOXO3/let-7c axis that requires future analysis. We suspect that under high oxidative 
stress, MST1, an essential activator of FOXO and repressor of AKT (82,186), is activated by 
PRDX1 decamers (formed by ten over-oxidized PRDX1 proteins) (79) under higher oxidative 
stress causing phosphorylation of FOXO3 on S207. This suggests FOXO3 nuclear localization 
under H2O2-induced stress may increase in the presence of decameric (over-oxidized) PRDX1. 
This is in alignment with our findings that PRDX1 binding to FOXO3 does not include over-
oxidized PRDX1 protein (Figure 3.5) and is dynamic as it decreases after 30 min in H2O2 treated 
cells (Figure 3.3). On the other hand, kinase activity of JNK and p38, are inhibited by PRDX1, 
perhaps accounting for the increased localization of FOXO3 in the nucleus in PRDX1-deficient 
cells compared to PRDX1 proficient cells (Figures 3.6 and 3.8). This suggests different roles for 








Figure 3.35: Model: Stepwise oxidation of PRDX1 regulates FOXO3 under oxidative stress. PRDX1 and FOXO3 interact in an oxidative 
stress-dependent way. This involves the catalytic/peroxidatic cysteine and C71 of PRDX1 and C31 and C150 of FOXO3. Our data strongly 
suggest disulfide bonding between PRDX1 and FOXO3 involving PRDX1 C52, C71, and C173 and FOXO3 C31 and C150 regulating the AKT-
induced phosphorylation of T32 on FOXO3 and 14-3-3 binding and dissociation. Nuclear localization and 14-3-3 dissociation of FOXO3 may be 
promoted by monoubiquitination or phosphorylation by over-oxidized PRDX1 activating MST1 or oxidative stress activation of JNK or p38. This 
results in expression in let-7b and let-7c and inhibition of migration. 
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our findings that PRDX1 binding to FOXO3 calibrates FOXO3 nuclear translocation through 
modulating AKT phosphorylation, we demonstrate that PI3K inhibition rescued translocation of 
C31S and C150S mutant FOXO3 to FOXOWT levels following H2O2 exposure (Figure 3.21).  
Collectively, these data suggest an oxidative stress dependent mechanism of FOXO3 
cytoplasmic loading, a protection and release that is directed through PRDX1 by binding to 
FOXO3 and coordinating its post-translational modifications (Figure 3.35). Accordingly, 
PRDX1-dependent protection of FOXO3 from repressive phosphorylation and degradation 
pathways would enable a FOXO3 reservoir not reliant on de novo synthesis of FOXO3 or T32 
dephosphorylation. The PRDX1-FOXO3 axis therefore is more than simply an inhibitory 
pathway, but rather, a redox-dependent signaling modulator enabling controlled bursts of 
FOXO3 nuclear translocation and gene expression. Based on our data shown here, we propose 
that PRDX1 builds a stepwise and redox-dependent FOXO3 cytoplasmic reservoir that is readily 
available once high H2O2 levels stimulate FOXO3 nuclear function.  
miRNAs are direct targets of transcription factors that are known as important tumor 
suppressors or oncogenic proteins. Yet, remarkably little is understood of miRNAs that are 
responsive to FOXOs. Consensus FOXO DNA binding motifs are present in the 5’ UTR of let-
7b and let-7c in several species (Figure 3.22). Interestingly, let-7b and let-7c-2 in mus musculus 
and rattus norvegicus are located in tandem and separated by 621 and 319 nucleotides, 
respectively. Our results establish for the first time that let-7b and let-7c are up-regulated by 
FOXO3 (Figures 3.24-3.27) directly to both of let-7c promoter regions (the distal host gene and 
the proximal intronic promoter) considered functional in let-7c transcription (147) (Figure 3.26). 
In addition, FOXO3 promoter binding is enhanced following 100 µM H2O2 treatment as 
compared to no treatment (Figure 3.26). These data define a new facet of FOXO3-mediated 
 95 
responses to oxidative stress, as our findings are consistent with prior reports that show let-7 
members are upregulated by ionizing radiation, genotoxic stress and peroxide (158,159). 
Intriguingly, we identified a novel FOXO3 target with direct tumor suppressive activity, as let-7 
miRNAs bind to 3’ UTRs of target oncogenes and cell cycle regulators and that reduced let-7 
expression has been shown to correlate with the development of cancers (187). 
Systemic deletion of FOXOs results in cancer in murine models in vivo, underscoring 
their role as bona fide tumor suppressors (188). Additionally, inactivating genetic mutations and 
reduced expression of FOXOs occur in human cancers (110,189) and suppression of FOXO 
function is critical in promoting evasion of apoptosis and is a significant occurrence in several 
hematological malignancies including Bcr-Abl+ leukemia (154,190). Notably, a more specific 
role has been identified for FOXO3 as an inhibitor of cancer cell motility (178,180) and wound 
healing (191), suggesting that FOXO3 may regulate cell motility. 
Similar to FOXOs, PRDX1 protects from tumor initiation (87), however, in contrast to 
FOXO3, several reports indicate poor prognosis for cancers with high expression of PRDX1 
(192-194). This is in line with our TCGA and survival analyses showing PRDX1 expression 
elevated in breast cancer patients with decreased survival (Figures 3.30 and 3.31). Importantly, 
these data support our findings that a PRDX1-FOXO3-let-7 axis exists in tumorigenesis. 
Furthermore, PRDX1-deficient MDA-MB-453 cells showed increased levels of let-7c (Figure 
3.33) and let-7 inhibition increased cell motility of MDA-MB-453 and MCF-7 breast cancer 
cells, both of which show low motility (195), with decreased PRDX1 expression (Figure 3.34). 
This finding is consistent with earlier studies showing that let-7 miRNAs inhibit motility of 
breast cancer cells by regulating genes in the actin cytoskeleton pathway (196). Given the 
findings of these studies and those presented here, it would be interesting in future studies to 
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determine let-7 miRNA targets that are controlled by PRDX1 and FOXO3 in cancer 
development. 
The free radical theory of aging posits that accumulated damage from oxidative events 
shortens lifespan. The fundamental importance of PRDX1 in protecting from the deleterious 
effects of oxidative stress is best illustrated by the multiple cancers and shortened lifespan in 
Prdx1-deficient mice (87). Moreover, hyperactivation of FOXO proteins have been implicated in 
extending life-span (197). Our data suggest that FOXO3 fine-tunes cellular homeostasis in 
response to cellular redox through integration with PRDX1. Because ROS are fundamental in 
driving the aging process and in the development of cancers, this new mechanism we describe 
here adds to our understanding of how the evolutionarily conserved FOXO C31 in conjunction 
with C150 may be instrumental in the regulation of aging and tumor suppression.  
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4.0  CONCLUSIONS 
4.1 SUMMARY 
Within the past decade, it has been found that, in addition to mediating the response to oxidative 
stress, the activity of several FOXO family members is also regulated by ROS signaling 
(82,93,107,108,162,198,199). This dissertation presents for the first time, evidence of a ROS-
dependent regulatory pathway of FOXO3 activity through the oxidative stress signaling sensor 
PRDX1. In response to H2O2, covalent disulfide bonds were formed between dimeric PRDX1 
and FOXO3. The formation of this complex controlled transcriptional activation of FOXO3 
through cytoplasmic sequestration. FOXO3 nuclear translocation and target gene activation had a 
concentration dependent response to H2O2, where inhibition of FOXO3 activity at low levels of 
stress could be overcome at higher levels. Upon investigation into the mechanistic of such an 
association, it was found that following H2O2 treatment, cysteine mutant FOXO3 proteins were 
unable to bind PRDX1, and that nuclear translocation and gene expression were lower when 
compared to those of WT FOXO3. In addition, this work identifies let-7 miRNAs as novel 
FOXO3 transcriptional targets, regulated in response to H2O2. Altogether, the studies presented 
here reveal a signaling pathway that enables PRDX1 to balance FOXO3 activity in response to a 
gradient of oxidative stress in the form of H2O2. 
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4.1.1 A model for how PRDX1 fine-tunes FOXO3 activity under oxidative stress 
The cysteine mutagenesis studies carried out establish that the peroxidatic cysteine (C52) and 
C71 of PRDX1 bind FOXO3 in response to oxidative stress. The data suggests thiol-disulfide 
exchange reactions occur between PRDX1 and FOXO3 involving dimeric PRDX1 C52, C173, 
and C71, which has not been previously described as participating in cell signaling, and FOXO3 
C31 and C150. Under increasing oxidative stress, we propose that the catalytic cysteines of the 
PRDX1 dimer form a fast forming and transient inter-disulfide bond with both C31 and C150 of 
FOXO3. First described in yeast, catalytic mechanisms for protein thiol oxidation involve the 
transfer of oxidative equivalents directly from a thiol peroxidase to a specific target protein 
through direct protein-protein contact (200). Recently, PRDX2 was found to act as a H2O2 signal 
receptor and transmitter for STAT3, forming a redox relay between the two proteins. Upon H2O2 
stimulation, a disulfide forms between PRDX2 and STAT3, transferring oxidation equivalents 
from PRDX2 to STAT3. The disulfide bond formation is shortly followed by the formation of 
STAT3 oxidation products, disulfide linked STAT3 dimers and tetramers, suggesting that it is 
the interaction with PRDX2 that triggers STAT3’s subsequent oxidation (152). A similar 
mechanism was previously described between PRDX1 and ASK1 (150), lending support to our 
proposed PRDX1-FOXO3 interaction. 
In addition, the covalent redox-controlled interaction between FOXO3 and PRDX1 
regulates FOXO3 localization through decreasing AKT FOXO3 phosphorylation, documenting 
the interplay between two different post-translational modifications. FOXO3 C31 is adjacent to 
FOXO3’s AKT phosphorylation site, T32, and the data from phosphorylation experiments show 
that FOXO3 C31 and C150 are highly phosphorylated at this as compared to WT FOXO3. The 
cysteine mutants also show no real response to changes in H2O2 levels. These results, in 
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conjunction with localization studies, lead us to conclude that FOXO3 C31 and C150 remain 
primarily sequestered in the cytosol, and inactive. 
Under high levels of H2O2 14-3-3, a chaperone protein involved in cytosolic 
sequestration, dissociates from FOXO3, and similarly, FOXO3 translocates into the nucleus. It is 
possible that after a certain period of time, over-oxidation of the PRDX1 catalytic cysteine is 
responsible for this, releasing FOXO3 or perhaps triggering a confirmation change that allows 
nuclear localization kinases to phosphorylate FOXO3. This possibility has been suggested for the 
MST1 and PRDX1 interaction, as high oxidative stress (H2O2) facilitates PRDX1 decamers due 
to overoxidation of its catalytic cysteine, which is required to activate MST1 (79). As MST1 
phosphorylation of FOXO3 leads to FOXO3 re-entering the nucleus it suggests that PRDX1 has 
a complex role in FOXO3 regulation, which suggests PRDX1-regulation of more than one 
signaling protein in the FOXO3 cascade.  Clearly, further studies are needed to properly 
investigate this possibility. 
4.1.2 The miRNA family let-7 identified as novel FOXO3 transactional targets 
miRNAs are direct targets of transcription factors, and are known to be both important tumor 
suppressors or oncogenic proteins. Even with miRNAs importance known, little is still 
understood of miRNAs that are responsive to FOXOs. Consensus FOXO DNA binding motifs 
are found conserved in the 5’ UTR of the breast cancer associated miRNAs, let-7b and let-7c in 
several species. Discovered in C. elegans, the let-7 family of miRNAs were first identified as key 
regulators of developmental timing, and are highly conserved across species (201). This research 
establishes for the first time, that FOXO3 upregulates the expression of both let-7b and let-7c, 
defining a new FOXO3 target, and a facet of its responses to oxidative stress. Moreover, these 
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results demonstrate that let-7b and let-7c expression is enhanced in response to H2O2 in a 
FOXO3-dependent fashion, with ChIP assays showing that H2O2 triggers FOXO3’s binding to 
the let-7c promoter region, findings that are consistent with previous investigations into the 
effect of stressors such as ionizing radiation, genotoxic stress and peroxide have on let-7 family 
member expression (158,159). Given that FOXOs integrate numerous cellular signals and serve 
as homeostatic regulators (154), the FOXO3-dependent upregulation of let-7 miRNAs in 
response to oxidative stress provides a founding example of the mechanistic link between 
FOXOs and let-7 miRNAs.  
Finally, our investigations into PRDX1’s effect on let-7 expression reveal let-7b and let-
7c expression is enhanced in the absence of PRDXl. Additionally, let-7 expression increases in 
PRDX1 knockdown breast cancer cell, along with an observed decrease in cell motility and 
invasion. Taken together, these findings point towards the existence of a PRDX1-FOXO3-let-7 
axis in tumorigenesis. PRDX1 sequesters FOXO3 in the cytosol for a period of time, and then 
upon release, FOXO3 translocate to the nucleus where it can to trigger the transcription of the 
let-7 miRNAs, and finally the newly transcribed let-7 miRNA are able to inhibit cancer cell 
motility and invasion, decreasing cancer metastasis (202). 
Our studies also expand upon the current knowledge that regulation of let-7 family 
members have been shown to be p53-dependent (158), providing another example of the 
functional overlap between p53 and FOXOs as tumor suppressors. let-7 miRNAs play an 
important role in regulating cell growth by binding to 3’ UTRs of target oncogenes and cell cycle 
regulators. In addition, down-regulation of let-7 expression has been shown to correlate with the 
development of cancers (187). Consequently, let-7 miRNAs are largely viewed as tumor 
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suppressor miRNAs, playing important roles in inhibition of metastasis and cancer stemness, 
particularly seen in breast cancer (202).  
4.2 FUTURE DIRECTIONS 
The research presented here is only one piece of the puzzle, and more studies are necessary to 
understand the role of redox signaling in transcription factor control and cancer progression. We 
have established that PRDX1 plays an important role in regulating FOXO3’s activity though 
cytosolic sequestration both by binding to FOXO3 and modifying FOXO3 phosphorylation by 
AKT. However, has discussed previously, PRDX1 also regulates the kinases MST1, JNK, and 
p38a, all of which are involved in the nuclear import of FOXO3, (Figure 4.1) 
(79,80,82,92,105,106,203). Taken together, an examination of this possible relationship between 
PRDX1, the nuclear entry kinases, and FOXO3, could give us a deeper understanding of 
FOXO3’s regulation, and how it’s activity is controlled. 
To elucidate the role of PRDX1 in the FOXO3 signaling cascade in more detail, a series 
of FOXO3 kinase mutants can be used to study the proposed dynamic. For example, each kinase 
phosphorylation site (S7 for p38a, S209 for MST1, and S574 for JNK) will be mutated to either 
an aspartic acid as a gain-of-function mutation, or an alanine as a loss-of-function mutation, 
creating eight different mutants with various configurations of gain-of-function or loss-of-
function. The kinase mutant will then be expressed in a tetracycline-inducible FOXO3 system in 
FOXO triple knockdown cells (204), followed by various H2O2 treatments (time and 
concentration). Differences in subcellular localization can then be analyze via western blotting 
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and immunofluorescence (IF), and changes in target specificity or expression will be determined 




Figure 4.1: PRDX1 promotes FOXO3 localization and differentially drives transcription of gene 





Figure 4.2: Experimental design flowchart. 
 
This analysis, will be then combined with experiments analyzing the activities if FOXO3 
phosphorylating kinases that are regulated by PRDX1: p38α, JNK and MST1. Since the 
oxidation of PRDX1’s catalytic cysteine is dependent on pro-oxidants and regulates signal 
transduction of PRDX1 binding partners, we should expect that under increasing oxidative stress 
PRDX1 is regulating each kinase differently. With this in mind, we then predict that this will 
translate into different dynamics in FOXO3 phosphorylation by MST1, JNK and p38a and may 
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therefore promote transcription of different FOXO3 targets differentially. Along those lines, 
phosphorylation of different sites on FOXO3 should alter target gene specificity. The studies can 
also be extended to include other post-translational FOXO3 modifications such as 
phosphorylation by AKT, mono-ubiquitination and acetylation, which have both been shown to 
affect the nuclear translocation of FOXO family members (96,107). In addition, FOXO3 
dephosphorylation by phosphatases may be considered, since protein phosphatase 2A (PP2A) 
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